{"gene":"HIPK2","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1999,"finding":"HIPK2 is covalently modified by SUMO-1 at nuclear speckles. HIPK2 contains a speckle-retention signal that interacts with the SUMO E2 conjugating enzyme mUBC9, and SUMO-1 modification correlates with HIPK2 localization to nuclear speckles (dots).","method":"Yeast two-hybrid, co-immunoprecipitation, cell-based localization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and localization experiments with functional correlation, single lab but multiple orthogonal methods","pmids":["10535925"],"is_preprint":false},{"year":2000,"finding":"HIPK2 is a member of the DYRK kinase subfamily; a conserved lysine residue in the kinase domain is essential for HIPK2 kinase function.","method":"Sequence alignment, kinase-dead mutant functional assay","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — mutagenesis of catalytic residue, single lab, single paper","pmids":["11120354"],"is_preprint":false},{"year":2001,"finding":"HIPK2 interacts with HMGI(Y) proteins through its PEST domain and phosphorylates HMGI(Y) in vitro; HIPK2 overexpression induces G2/M cell cycle arrest.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assay, colony assay, flow cytometry","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay plus co-IP plus functional assay, single lab","pmids":["11593421"],"is_preprint":false},{"year":2001,"finding":"HIPK2 overexpression stabilizes p53 protein and decreases MDM2 protein levels (post-transcriptionally), thereby increasing p53 transcriptional activity; kinase-dead HIPK2 does not produce these effects.","method":"Overexpression, reporter assay, western blot, kinase-dead mutant","journal":"BMC molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead mutant controls and functional reporter assays, single lab","pmids":["11532197"],"is_preprint":false},{"year":2002,"finding":"HIPK2 interacts with RanBPM in the nucleus; both wild-type and kinase-dead HIPK2 co-localize with RanBPM in defined nuclear structures.","method":"Yeast two-hybrid, co-immunoprecipitation, co-localization","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP and localization, no functional follow-up, single lab","pmids":["12220523"],"is_preprint":false},{"year":2002,"finding":"HIPK2 interacts with p73α via the oligomerization domain region (aa 812-907 of HIPK2), co-localizes with p73 and p53 in nuclear bodies, and potentiates p73/p53-induced transcriptional repression and apoptotic response to genotoxic drugs.","method":"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, confocal microscopy, reporter assay, FACS","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (GST pulldown, co-IP, reporter, FACS) in one study, single lab","pmids":["11925430"],"is_preprint":false},{"year":2003,"finding":"Endogenous HIPK2 and HIPK3 reside in novel subnuclear HIPK domains distinct from PML-NBs; PML isoform IV (but not III) recruits HIPK2 to PML-NBs; PML is required for HIPK2-mediated p53 Ser46 phosphorylation and antiproliferative function.","method":"Immunofluorescence, confocal microscopy, PML-knockout fibroblasts, functional reporter assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — PML-null cell experiments plus isoform-specific recruitment and functional readout, single lab, multiple orthogonal methods","pmids":["12907596"],"is_preprint":false},{"year":2003,"finding":"HIPK2 co-localizes with Daxx in PML nuclear bodies, interacts with Daxx in vitro and in vivo via its kinase domain, phosphorylates Daxx, and activates the JNK pathway (via Daxx-MKK4/MKK7) to potentiate TGF-β-induced apoptosis; RNAi knockdown of HIPK2 inhibits TGF-β-induced JNK activation.","method":"Co-immunoprecipitation, in vitro binding, in vitro kinase assay, siRNA knockdown, JNK activation assay, apoptosis assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, in vitro kinase assay, RNAi knockdown with defined signaling readout, single lab, multiple methods","pmids":["14678985"],"is_preprint":false},{"year":2003,"finding":"TP53INP1 isoforms physically interact with HIPK2 and p53, co-localize in PML nuclear bodies, and cooperate with HIPK2 to regulate p53 transcriptional activity on p21, mdm2, pig3, and bax promoters.","method":"Co-immunoprecipitation, confocal microscopy, reporter assay, overexpression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP and functional reporter assays, single lab","pmids":["12851404"],"is_preprint":false},{"year":2003,"finding":"HIPK2 (PKM) modifies PML nuclear body (ND10) structure through both its kinase domain and a SUMO-1 interaction motif, and alters post-translational modification of PML.","method":"Overexpression, immunofluorescence, western blot","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — kinase-dead and SIM mutant analyses with localization readout, single lab","pmids":["12565818"],"is_preprint":false},{"year":2004,"finding":"Axin interacts with HIPK2 and forms a multimeric complex with p53; Axin stimulates HIPK2-mediated phosphorylation of p53 at Ser46, facilitating p53-dependent transcription and apoptosis. The Axin-binding region of HIPK2 acts as a putative autoinhibitory domain.","method":"Co-immunoprecipitation, siRNA knockdown, kinase-dead mutant, reporter assay, apoptosis assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, siRNA knockdown, kinase-dead controls, multiple functional readouts, single lab","pmids":["15526030"],"is_preprint":false},{"year":2004,"finding":"Wnt-1 signal activates a TAK1→HIPK2→NLK pathway that phosphorylates c-Myb at multiple sites through direct NLK-c-Myb interaction facilitated by HIPK2, leading to c-Myb ubiquitination and proteasomal degradation.","method":"Co-immunoprecipitation, in vitro kinase assay, overexpression, ubiquitination assay, differentiation assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay, co-IP, functional degradation assay, multiple orthogonal approaches, single lab","pmids":["15082531"],"is_preprint":false},{"year":2004,"finding":"HIPK2 interacts with the POU-domain transcription factor Brn3a, promotes Brn3a DNA binding, but suppresses Brn3a-dependent transcription of brn3a, trkA, and bcl-xL; targeted deletion of HIPK2 increases TrkA and Bcl-xL expression and reduces apoptosis in trigeminal ganglion neurons.","method":"Co-immunoprecipitation, reporter assay, HIPK2 knockout mice, immunohistochemistry, neuronal survival assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP, reporter assays, and genetic knockout with specific neuronal phenotypes, single lab, multiple methods","pmids":["15492043"],"is_preprint":false},{"year":2004,"finding":"Herpes simplex virus US11 protein interacts with HIPK2 through the PEST domain of HIPK2, alters HIPK2 subcellular distribution, and protects cells from HIPK2-induced cell growth arrest.","method":"Yeast two-hybrid, co-immunoprecipitation, localization, growth assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP, domain mapping, and functional assay, single lab","pmids":["14990717"],"is_preprint":false},{"year":2005,"finding":"HIPK2 is SUMO-1 modified at Lys25 in vitro and in vivo; this sumoylation is phosphorylation-dependent (kinase-dead HIPK2 is not efficiently sumoylated) and inhibits HIPK2-induced JNK activation and p53-independent antiproliferative function. SUMO protease SuPr-1 co-localizes with HIPK2 in PML nuclear bodies and deconjugates SUMO-1 from HIPK2.","method":"In vitro SUMOylation, co-immunoprecipitation, siRNA, reporter assay, kinase-dead mutant","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of SUMOylation plus kinase-dead mutant and functional assays, single lab, multiple methods","pmids":["15958389"],"is_preprint":false},{"year":2005,"finding":"HIPK2 depletion inhibits PCAF-mediated p53 acetylation and p53 binding to the p21Waf1 promoter following nonapoptotic DNA damage; HIPK2 cooperates with PCAF to selectively induce p53 transcriptional activity toward p21Waf1.","method":"siRNA knockdown, chromatin immunoprecipitation, reporter assay, western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and siRNA with functional reporter readout, single lab","pmids":["15897882"],"is_preprint":false},{"year":2005,"finding":"Phosphorylation-dependent SUMO modification of HIPK2 at Lys25 differentially regulates its interactions: sumoylation disrupts interaction with Groucho corepressor and inhibits HIPK2 regulation of Groucho-mediated transcriptional repression, but does not affect p53-mediated transactivation.","method":"In vitro SUMOylation, co-immunoprecipitation, reporter assay, kinase-dead mutant","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro sumoylation and functional reporter assay, single lab","pmids":["15896780"],"is_preprint":false},{"year":2005,"finding":"HIPK2 interacts with MDM2 in vitro and in vivo, phosphorylates MDM2 in vitro, and promotes MDM2 nuclear export and proteasomal degradation in a p53-independent manner; additionally, HIPK2-dependent p53 Ser46 phosphorylation suppresses MDM2 at the transcriptional level.","method":"Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, western blot, subcellular fractionation","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay and co-IP with siRNA validation, single lab, two orthogonal methods","pmids":["16212962"],"is_preprint":false},{"year":2005,"finding":"SENP1 desumoylates HIPK2 both in vitro and in vivo; desumoylation of HIPK2 by SENP1 leads to dissociation of HIPK2 from nuclear bodies; SENP1 contains a nuclear export sequence regulating its cytoplasmic-nuclear shuttling which in turn controls HIPK2 desumoylation.","method":"In vitro desumoylation assay, co-immunoprecipitation, SENP1 mutant analysis, localization","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro desumoylation reconstitution and functional localization assay, single lab","pmids":["16253240"],"is_preprint":false},{"year":2006,"finding":"HIPK2 forms a complex with AML1 and p300, phosphorylates both AML1 and p300 to stimulate their transcriptional and histone acetyltransferase (HAT) activities; p300 phosphorylation is triggered by phosphorylated AML1 as well as by PU.1, c-MYB, c-JUN and c-FOS. In Hipk1/2 double-knockout mouse embryos, phosphorylation of AML1 and p300 is impaired.","method":"Co-immunoprecipitation, in vitro kinase assay, HAT activity assay, double-knockout mice","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay, co-IP, genetic knockout with biochemical readout, single lab, multiple orthogonal methods","pmids":["16917507"],"is_preprint":false},{"year":2006,"finding":"HIPK2 is required for TGFβ-mediated survival of midbrain dopamine neurons; HIPK2 function depends on its interaction with receptor-regulated Smads to activate TGFβ target genes; loss of HIPK2 causes selective dopamine neuron apoptosis during programmed cell death.","method":"Hipk2 knockout mice, TGFβ3 survival assay, Smad interaction studies","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout phenotype validated with biochemical Smad interaction, replicated in Tgfbeta3-null comparison, single lab","pmids":["17159989"],"is_preprint":false},{"year":2007,"finding":"MDM2-mediated proteasomal degradation of HIPK2 prevents p53 Ser46 phosphorylation during cytostatic (non-severe) DNA damage; a degradation-resistant HIPK2 mutant converts growth arrest to apoptosis. p53 actively represses HIPK2 via MDM2 to inhibit the apoptotic pathway.","method":"Degradation-resistant HIPK2 mutant, MDM2 overexpression, siRNA, p53 Ser46 phosphorylation assay, apoptosis assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple mutant and knockdown experiments with defined apoptotic readouts, single lab, multiple orthogonal methods","pmids":["17349959"],"is_preprint":false},{"year":2007,"finding":"Daxx associates with the Axin/HIPK2/p53 complex; Axin-Daxx interaction is enhanced by UV irradiation, and Axin tethers Daxx to p53 to cooperate with HIPK2-mediated Ser46 phosphorylation and selectively activate PUMA expression.","method":"Co-immunoprecipitation, siRNA knockdown, reporter assay, colony formation assay, cell death assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP plus siRNA with functional readout, single lab","pmids":["17210684"],"is_preprint":false},{"year":2007,"finding":"HIPK2 suppresses LEF1/β-catenin-mediated transcriptional activation of cyclin D1 by recruiting the corepressor CtBP through its C-terminal YH domain; deletion of the YH domain abolishes CtBP recruitment and loss of HIPK2 expands the epidermal stem cell compartment.","method":"HIPK2 knockout mice, reporter assay, YH-domain deletion mutant, gene expression analysis, skin carcinogenesis model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout plus domain-deletion mutant plus reporter assay with specific phenotypic readout, single lab, multiple methods","pmids":["17666529"],"is_preprint":false},{"year":2007,"finding":"HIPK2 phosphorylates HMGA1a at Ser-35, Thr-52, and Thr-77 (and HMGA1b at Thr-41 and Thr-66), reducing HMGA1a binding affinity to DNA; the site preference of HIPK2 differs from that of cdc2.","method":"In vitro kinase assay, mass spectrometry, electrophoretic mobility shift assay","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay with MS mapping and functional DNA-binding assay, single lab","pmids":["17960875"],"is_preprint":false},{"year":2008,"finding":"HIPK2 is an unstable protein that interacts with E3 ubiquitin ligase Siah-1 in unstressed cells; Siah-1 knockdown increases HIPK2 stability, and Siah-1 promotes HIPK2 polyubiquitination and proteasomal degradation. DNA damage disrupts the HIPK2-Siah-1 complex via ATM/ATR-dependent phosphorylation of Siah-1 at Ser19, stabilizing HIPK2.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, ATM/ATR inhibitor, phosphorylation site mutant","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, ubiquitination assay, genetic and pharmacological perturbation with mechanistic site mapping, replicated across multiple assays","pmids":["18536714"],"is_preprint":false},{"year":2008,"finding":"Under normoxia, HIPK2 phosphorylates Siah2 at Ser26, Ser28, and Ser68, weakening mutual binding and destabilizing Siah2. Hypoxia increases HIPK2/Siah2 interaction, enabling efficient HIPK2 polyubiquitylation and proteasomal degradation; hypoxia-induced HIPK2 elimination is reduced in Siah2-deficient cells.","method":"Co-immunoprecipitation, ubiquitination assay, Siah2-knockout cells, hypoxia treatment, phosphorylation mapping","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, phosphorylation mapping, genetic (Siah2-KO) validation, multiple orthogonal methods, single lab","pmids":["19043406"],"is_preprint":false},{"year":2008,"finding":"PML protects HIPK2 and p300 from SCFFbx3-mediated proteasomal degradation; Fbx3 forms SCF(Fbx3) ubiquitin ligase that promotes ubiquitin-proteasome degradation of HIPK2; PML, Fbx3, and HIPK2 synergistically activate p53-induced transcription. The leukemia-associated PML-RARα induces HIPK2 degradation.","method":"Purification of PML complex, co-immunoprecipitation, ubiquitination assay, reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — complex purification plus ubiquitination assay plus functional reporter, single lab, multiple orthogonal methods","pmids":["18809579"],"is_preprint":false},{"year":2009,"finding":"HIPK2 phosphorylates the transcription factor ZBTB4, leading to its proteasomal degradation under normal growth conditions and upon DNA damage; kinase-deficient HIPK2 does not cause ZBTB4 degradation; the two proteins interact in vitro and colocalize in vivo.","method":"In vitro binding, co-immunoprecipitation, kinase-dead mutant, siRNA, western blot","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro kinase assay and kinase-dead mutant with degradation readout, single lab","pmids":["19448668"],"is_preprint":false},{"year":2009,"finding":"Siah1 is an E3 ubiquitin ligase for HIPK2, targeting it for poly-ubiquitination and proteasomal degradation; this degradation is blocked by MLK-3, EBV LMP-1, or DNA-damaging stimuli.","method":"Co-immunoprecipitation, ubiquitination assay, DNA damage treatment, western blot","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP and ubiquitination assay, single lab, replicates finding from PMID 18536714","pmids":["19250734"],"is_preprint":false},{"year":2010,"finding":"HIPK2 is a new kinase for ATF1, phosphorylating it at Ser198 (not Ser63); HIPK2 overrides ATF1-mediated repression of ferritin H and other antioxidant genes at the ARE in a kinase-activity-dependent manner; induction of antioxidant genes by genotoxic stress is impaired in HIPK2-null MEFs.","method":"In vitro kinase assay, HIPK2-null MEFs, reporter assay, RT-PCR","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay, knockout MEFs with gene expression readout, reporter assay, multiple methods, single lab","pmids":["20980392"],"is_preprint":false},{"year":2010,"finding":"HIPK2 phosphorylates β-catenin at Ser33 and Ser37, targeting it for proteasomal degradation without requiring a priming kinase; HIPK2 knockdown increases β-catenin nuclear accumulation and Wnt target gene expression; co-injection of HIPK2 mRNA blocks β-catenin-induced axis duplication in Xenopus embryos.","method":"In vitro kinase assay, site-directed mutagenesis, siRNA, reporter assay, Xenopus embryo assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, siRNA knockdown, and in vivo Xenopus rescue, single lab, multiple methods","pmids":["20307497"],"is_preprint":false},{"year":2010,"finding":"HIPK2 contains a SUMO-interacting motif (SIM) that binds all three major SUMO isoforms non-covalently; SIM mutation prevents localization of HIPK2 to nuclear speckles and PML nuclear bodies, disrupts colocalization with Pc2, and alters HIPK2 functional activity.","method":"SIM point mutant analysis, co-immunoprecipitation, immunofluorescence, SUMO binding assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mutant analysis with localization and functional readouts, single lab","pmids":["21145359"],"is_preprint":false},{"year":2010,"finding":"SIM-mediated HIPK2 recruitment to PML-IV nuclear bodies is required for HIPK2-mediated p53 Ser46 phosphorylation and induction of apoptosis; HIPK2 specifically co-localizes with PML-I and PML-IV, and HIPK2 SIM mutants fail to activate or phosphorylate p53.","method":"Mutational analysis, co-immunoprecipitation, immunofluorescence, colony formation assay, p53 phosphorylation assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — SIM mutant with localization and functional phosphorylation readout, single lab","pmids":["21192925"],"is_preprint":false},{"year":2011,"finding":"HIPK2 phosphorylates ΔNp63α at Thr397, promoting its proteasomal degradation in response to DNA damage; the non-phosphorylatable ΔNp63α-T397A mutant is not degraded and confers chemoresistance.","method":"In vitro kinase assay, site-directed mutagenesis, siRNA, western blot, cell survival assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with phosphorylation site mutagenesis and functional rescue experiment, single lab, multiple orthogonal methods","pmids":["21602882"],"is_preprint":false},{"year":2011,"finding":"Zyxin stabilizes HIPK2 by interfering with Siah-1 dimerization; Zyxin co-localizes with HIPK2 at the cytoskeleton and nucleus, physically interacts with Siah-1, and its depletion accelerates HIPK2 proteasomal degradation and reduces DNA damage-induced p53 Ser46 phosphorylation.","method":"Co-immunoprecipitation, siRNA knockdown, western blot, p53 phosphorylation assay, caspase activation assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, mechanistic model with dimerization assay, siRNA with functional phosphorylation readout, single lab","pmids":["21248071"],"is_preprint":false},{"year":2011,"finding":"HIF-1α upregulation induces proteasomal degradation of HIPK2, thereby antagonizing p53-mediated apoptosis; HIF-1α inhibition by siRNA, dominant-negative HIF-1α, or zinc re-establishes HIPK2 levels and p53-mediated chemosensitivity.","method":"siRNA knockdown, dominant-negative HIF-1α, zinc supplementation, western blot, apoptosis assay","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple perturbations converging on HIPK2 degradation, single lab","pmids":["21248371"],"is_preprint":false},{"year":2012,"finding":"HIPK2 binds and phosphorylates histone H2B at S14 (H2B-S14P); HIPK2 and H2B co-localize at the midbody during cytokinesis; HIPK2 depletion causes loss of H2B-S14P at the midbody, cytokinesis failure, and tetra/polyploidization. Phosphomimetic H2B-S14D rescues cytokinesis in HIPK2-null cells.","method":"Co-immunoprecipitation, in vitro kinase assay, HIPK2 knockout/RNAi, phosphomimetic mutant rescue, live-cell imaging","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, genetic KO, phosphomimetic rescue, and localization, multiple orthogonal methods and replicated across approaches","pmids":["22658722"],"is_preprint":false},{"year":2012,"finding":"HIPK2 is a key regulator of kidney fibrosis; it activates p53, TGF-β-Smad3, and Wnt-Notch pathways in renal tubular epithelial cells to drive apoptosis and EMT; HIPK2 knockout attenuates kidney fibrosis in multiple murine models; HIV-induced oxidative stress increases HIPK2 by inhibiting Siah1-mediated proteasomal degradation.","method":"Hipk2-knockout mice, siRNA knockdown, pathway activation assays, mouse fibrosis models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout in multiple fibrosis models with pathway-level mechanistic validation, replicated across multiple disease contexts","pmids":["22406746"],"is_preprint":false},{"year":2012,"finding":"HIPK2 is heavily autophosphorylated; cis-autophosphorylation at Y354 and S357 in the activation loop is essential for kinase activity, substrate binding, and interaction with Pin1; HIPK2 activation-loop phosphorylation is required for its biological activity as regulator of gene expression and cell proliferation.","method":"In vitro kinase assay, phosphosite mutants, cis-autophosphorylation assay, reporter assay, cell proliferation assay","journal":"Journal of molecular cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of cis-autophosphorylation with mutagenesis and multiple functional assays, single lab","pmids":["23000554"],"is_preprint":false},{"year":2013,"finding":"HIPK2 autophosphorylates at Thr880/Ser882 upon DNA damage; this autophosphorylation creates a binding signal for the phospho-specific isomerase Pin1, which stabilizes HIPK2 by inhibiting its polyubiquitination and modulating Siah-1-HIPK2 interaction; Pin1 is required for DNA damage-induced HIPK2 stabilization, p53 Ser46 phosphorylation, and apoptosis in zebrafish.","method":"Autophosphorylation assay, co-immunoprecipitation, ubiquitination assay, zebrafish in vivo model, site-directed mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro autophosphorylation reconstitution, Pin1 binding, ubiquitination, and in vivo zebrafish validation with mutagenesis, multiple methods and replicated in vivo","pmids":["24145406"],"is_preprint":false},{"year":2013,"finding":"Autophosphorylation of HIPK2 at activation-loop Y354 is an autocatalytic event essential for S/T-kinase activity; prevention of Y354 phosphorylation by mutagenesis or purvalanol A reduces HIPK2 kinase activity, induces aberrant tyrosine-kinase activity in cis, and causes cytoplasmic relocalization of HIPK2.","method":"Site-directed mutagenesis, kinase inhibitor, in vitro kinase assay, subcellular localization","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis and inhibitor with in vitro kinase assay and localization readout, single lab, multiple orthogonal methods","pmids":["23485397"],"is_preprint":false},{"year":2013,"finding":"HIPK2 identifies WIP1 phosphatase as a substrate, phosphorylating and targeting it for proteasomal degradation in unstressed cells; upon ionizing radiation, ATM-dependent AMPKα2-mediated HIPK2 phosphorylation dissociates WIP1 from HIPK2, allowing WIP1 stabilization and termination of ATM signaling.","method":"Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, hipk2-knockout mice, γ-H2AX assay, cell cycle checkpoint analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, in vitro kinase assay, knockout mice with in vivo phenotype, multiple orthogonal methods, single lab","pmids":["23871434"],"is_preprint":false},{"year":2013,"finding":"Han11/DCAF7/WDR68 is a scaffold protein that directly binds HIPK2 and MEKK1, coupling these kinases together; Han11 controls the threshold, amplitude, and kinetics of HIPK2- and MEKK1-driven signaling; loss of Han11 lowers the threshold of HIPK2-triggered transcriptional responses.","method":"In vitro binding, co-immunoprecipitation, siRNA knockdown in C. elegans and human cells, reporter assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vitro direct binding, reciprocal co-IP, functional knockdown in two organisms, single lab, multiple methods","pmids":["20940704"],"is_preprint":false},{"year":2013,"finding":"Src kinase phosphorylates HIPK2 at nine tyrosine residues (including Tyr354 in the kinase domain), increases HIPK2 half-life by interfering with Siah-1-mediated degradation, and redistributes HIPK2 from the nucleus to the cytoplasm, thereby decreasing drug-induced p53 Ser46 phosphorylation and apoptosis.","method":"Mass spectrometry, phosphorylation-specific antibody, co-immunoprecipitation, half-life assay, subcellular fractionation, apoptosis assay","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS phosphosite identification, co-IP, stability assay, localization and functional apoptosis readout, single lab","pmids":["24196445"],"is_preprint":false},{"year":2013,"finding":"HIPK1 and HIPK2 are transcriptional corepressors that regulate TGF-β-dependent angiogenesis; TGF-β-TAK1 signaling activates HIPK2 by phosphorylating conserved Y-361 within the kinase domain; point mutation Y361A abolishes HIPK2 corepressor activity; the effect of HIPK2 is mediated through interaction with transcription factor MEF2C.","method":"Hipk1/2 knockout mice, siRNA knockdown in endothelial cells, reporter assay, Y361 mutant, co-immunoprecipitation","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout, reporter assay with specific mutant, co-IP for MEF2C interaction, multiple methods, single lab","pmids":["23565059"],"is_preprint":false},{"year":2014,"finding":"XAF1 blocks Siah2 interaction with and ubiquitination of HIPK2, thereby stabilizing HIPK2 and stimulating HIPK2-mediated Ser46 phosphorylation of p53; XAF1 physically interacts with Siah2 through its zinc finger domains 5 and 6.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA, p53 phosphorylation assay, ZF domain mutants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ubiquitination assay, and domain-specific mutants, single lab","pmids":["25313037"],"is_preprint":false},{"year":2014,"finding":"Hipk2 and PP1c cooperate to maintain Dvl protein levels; Hipk2 facilitates PP1c-mediated dephosphorylation of Dvl via its C-terminal domain, blocking Itch-mediated ubiquitination and degradation of phosphorylated Dvl; inhibition of Hipk2 or PP1c reduces Dvl levels and suppresses Wnt/β-catenin and Wnt/PCP signaling in cells and zebrafish.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA, zebrafish embryo assay, Wnt reporter assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, ubiquitination assay, and in vivo zebrafish validation, multiple orthogonal methods, single lab","pmids":["25159144"],"is_preprint":false},{"year":2015,"finding":"HIPK2 phosphorylates SIRT1 at Ser682 upon lethal DNA damage; this phosphorylation inhibits SIRT1 deacetylase activity by disrupting the SIRT1-AROS activator complex, promoting p53 acetylation and apoptotic target gene expression; SIRT1-HIPK2 co-localize at PML nuclear bodies, and PML depletion abrogates SIRT1 Ser682 phosphorylation.","method":"Co-immunoprecipitation, in vitro kinase assay, SIRT1 activity assay, siRNA, ChIP, PML-knockdown","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with identified substrate site, SIRT1 activity assay, co-IP, PML knockdown with defined phosphorylation readout, single lab, multiple methods","pmids":["26113041"],"is_preprint":false},{"year":2016,"finding":"ER stress (induced by tunicamycin or SOD1G93A) activates HIPK2 by phosphorylating Ser359/Thr360 in its activation loop; activated HIPK2 promotes ER-stress-induced cell death via the IRE1α-ASK1-JNK pathway; loss of HIPK2 delays disease onset and reduces motor neuron death in SOD1G93A ALS mice.","method":"Phospho-specific antibody, HIPK2-knockout mice, kinase assay, in vivo ALS model, cell death assay","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — phospho-site identification, HIPK2-KO with in vivo phenotype in ALS model, IRE1α-ASK1-JNK pathway placement, single lab, multiple methods","pmids":["27321923"],"is_preprint":false},{"year":2016,"finding":"HIPK2 phosphorylates MeCP2, and the resulting p-MeCP2 suppresses processing of miR-25, leading to elevated NOX4 in diabetic nephropathy; SIAH1 decreases in diabetic glomeruli, correlating with increased HIPK2 protein stability.","method":"siRNA knockdown, western blot, qRT-PCR, streptozotocin diabetic mouse model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA-based epistasis with defined molecular pathway, single lab, single mouse model","pmids":["27941951"],"is_preprint":false},{"year":2016,"finding":"DCAF7/WDR68 serves as an adaptor for HIPK2 binding to the adenovirus E1A oncoprotein; DCAF7 is required for HIPK2-mediated hyperphosphorylation of E1A; DCAF7 binds HIPK2 via a conserved 12-amino acid motif; the closely related HIPK1 does not bind DCAF7.","method":"Immunoprecipitation, pulldown, DCAF7 motif mutant, overexpression phosphorylation assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, pulldown, and functional phosphorylation assay with motif mutants, single lab","pmids":["27307198"],"is_preprint":false},{"year":2017,"finding":"HIPK2 is a direct transcriptional target of NRF2; a functional NRF2 binding site was identified in the HIPK2 gene locus; HIPK2 is also required for robust NRF2 responsiveness in cells and in vivo, establishing a bidirectional HIPK2-NRF2 regulatory loop.","method":"ChIP, reporter assay, gain-of-function, loss-of-function (HIPK2 KO mice), NRF2 target gene assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP identifies functional NRF2 binding site, KO mice validate requirement, gain/loss-of-function, single lab","pmids":["28692050"],"is_preprint":false},{"year":2018,"finding":"HIPK2-JNK-c-Jun signaling suppresses transcription of Grin2a and Grin2c (encoding GluN2A and GluN2C NMDA receptor subunits); loss of HIPK2 decreases JNK-c-Jun signaling, derepresses GluN2A/GluN2C expression, and increases GluN2A/GluN2B ratio in synapse and mitochondria, activating the ERK-CREB prosurvival pathway.","method":"Hipk2-knockout mice, transcriptomic analysis, JNK activity assay, synaptic fractionation, electrophysiology","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with transcriptomic, biochemical, and synaptic pathway readouts, multiple methods, single lab","pmids":["29581378"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of the HIPK2 kinase domain bound to CX-4945 at 2.2 Å reveals an active conformation stabilized by activation-loop phosphorylation; the CMGC-insert region and the αC-β4 loop insert adopt conformations unique among DYRK-family kinases; CX-4945 engages the active site in a hybrid CK2α/Pim1-like binding mode.","method":"X-ray crystallography at 2.2 Å","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with defined active conformation and inhibitor binding mode, replicated via structural analysis","pmids":["31341017"],"is_preprint":false},{"year":2019,"finding":"HIPK2 binds and phosphorylates the microtubule-severing enzyme spastin at Ser268; midbody-localized spastin phosphorylation at S268 is HIPK2-dependent; non-phosphorylatable spastin-S268A fails to localize at the midbody and cannot rescue abscission defects in HIPK2-depleted cells; phosphomimetic spastin-S268D restores midbody localization and successful abscission.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, immunofluorescence, cytokinesis assay","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with site-specific mutagenesis, phosphomimetic rescue, and functional abscission readout, single lab, multiple methods","pmids":["31284535"],"is_preprint":false},{"year":2019,"finding":"EGFR/STAT3 signaling drives HIPK2 expression in kidney tubular epithelial cells; ChIP analysis shows STAT3 directly binds the promoter region of HIPK2; HIPK2 silencing attenuates vancomycin-induced AKI-to-CKD progression.","method":"ChIP analysis, EGFR mutant mice, gefitinib treatment, HIPK2 siRNA, western blot","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP with STAT3 promoter binding plus genetic and pharmacological validation, single lab","pmids":["31131063"],"is_preprint":false},{"year":2021,"finding":"HIPK2 binds and phosphorylates HDAC3 at Ser374, inhibiting its deacetylase activity, thus preventing deacetylation of NF-κB p65 at Lys218 and suppressing NF-κB-driven inflammatory gene expression in macrophages.","method":"Co-immunoprecipitation, in vitro kinase assay, HDAC3 activity assay, site-directed mutagenesis, HIPK2 knockout mice, CLP and LPS models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with specific phosphosite, HDAC3 activity assay, genetic KO mice with in vivo sepsis model, multiple orthogonal methods","pmids":["34244427"],"is_preprint":false},{"year":2021,"finding":"Upon DNA damage, ATM phosphorylates SPOP at Ser119, potentiating SPOP binding to HIPK2 and triggering non-degradative ubiquitination of HIPK2; this modification increases HIPK2-mediated phosphorylation of HP1γ, promoting HP1γ dissociation from H3K9me3 to initiate DNA damage repair; cancer-associated SPOP mutations abrogate this axis.","method":"Co-immunoprecipitation, ubiquitination assay, in vitro kinase assay, phospho-specific antibodies, SPOP mutants, ChIP","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, ubiquitination assay, phospho-mutant analysis, functional DNA-repair readout, single lab, multiple methods","pmids":["34133717"],"is_preprint":false},{"year":2021,"finding":"HIPK2 suppression attenuates cardiomyocyte apoptosis after myocardial infarction via decreasing p53 phosphorylation; miR-222 targets HIPK2 to mediate exercise-induced cardioprotection; protective effect of HIPK2 suppression is reversed by p53 activators.","method":"HIPK2-knockout mice, HIPK2 inhibitor, lentiviral knockdown, p53 activator rescue, OGD/R assay in hESC-CMs","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mice plus inhibitor with in vivo MI model and p53 activator epistasis, single lab","pmids":["34837851"],"is_preprint":false},{"year":2022,"finding":"HIPK2 inhibition protects against pathological cardiac remodeling by reducing EGR3 and CLEC4D expression via ERK1/2-CREB inhibition in cardiomyocytes, and by suppressing Smad3 phosphorylation in cardiac fibroblasts.","method":"HIPK2 knockout mice, pharmacological inhibitors, microarray, siRNA rescue (EGR3/CLEC4D/Smad3), TAC model","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mice plus microarray-identified targets with rescue experiments, single lab, multiple methods","pmids":["36182775"],"is_preprint":false}],"current_model":"HIPK2 is a nuclear serine/threonine (and dual-specificity) kinase that is activated by cis-autophosphorylation of its activation loop (Y354/S357) and by upstream kinases (ATM, ATR, TGF-β-TAK1), and whose stability is tightly regulated by competing ubiquitin E3 ligases (Siah-1, Siah2, MDM2, SCFFbx3) and stabilizing factors (Zyxin, XAF1, PML, Pin1); upon severe genotoxic or ER stress, HIPK2 phosphorylates p53 at Ser46 to drive apoptotic gene expression, phosphorylates and inhibits SIRT1 (Ser682) to permit p53 acetylation, phosphorylates and degrades the anti-apoptotic ΔNp63α (T397) and WIP1, and controls cytokinesis by phosphorylating histone H2B (S14) and the microtubule-severing enzyme spastin (S268) at the midbody; HIPK2 also represses Wnt/β-catenin signaling by directly phosphorylating β-catenin (Ser33/37) for proteasomal degradation, suppresses NF-κB-driven inflammation by phosphorylating HDAC3 (Ser374), and modulates TGF-β-Smad, JNK-c-Jun, and NRF2 pathways in a context-dependent manner, with its crystal structure showing an active DYRK-like kinase domain with a unique CMGC-insert conformation."},"narrative":{"mechanistic_narrative":"HIPK2 is a nuclear DYRK-family serine/threonine kinase that acts as a stress-responsive signaling hub coupling genotoxic and ER stress to apoptotic gene expression, developmental transcriptional control, and cytokinesis [PMID:11120354, PMID:17349959, PMID:22658722]. Its catalytic activity depends on cis-autophosphorylation of activation-loop residues Y354 and S357, which is required for substrate binding and for nuclear retention, and a crystal structure of the kinase domain confirms an active conformation with a CMGC-insert region structurally unique among DYRK kinases [PMID:23000554, PMID:23485397, PMID:31341017]. HIPK2 localizes to subnuclear HIPK domains and is recruited to PML nuclear bodies through both covalent SUMO-1 modification at Lys25 and a non-covalent SUMO-interacting motif, and this PML/SUMO-dependent compartmentalization is required for HIPK2-mediated p53 Ser46 phosphorylation and apoptosis [PMID:10535925, PMID:12907596, PMID:15958389, PMID:21145359, PMID:21192925]. The central pro-apoptotic output is phosphorylation of p53 at Ser46—potentiated by the Axin/Daxx scaffold and by inhibitory phosphorylation of SIRT1 (Ser682) that permits p53 acetylation—driving selective apoptotic and antioxidant target gene expression [PMID:15526030, PMID:17210684, PMID:26113041]. HIPK2 stability is the principal switch governing this decision: in unstressed or growth states it is held low by E3 ligases Siah-1, Siah2, MDM2, and SCF(Fbx3), while DNA damage (via ATM/ATR), the stabilizers Zyxin, XAF1, PML, and Pin1, and oncogenic regulators (HIF-1α, Src) tune its abundance to set the apoptotic threshold [PMID:17349959, PMID:18536714, PMID:19043406, PMID:18809579, PMID:21248071, PMID:24145406, PMID:24196445, PMID:25313037]. Beyond p53, HIPK2 directly phosphorylates and degrades anti-apoptotic ΔNp63α (T397) and the WIP1 phosphatase, represses Wnt/β-catenin signaling by phosphorylating β-catenin at Ser33/37 for degradation, modulates TGF-β-Smad, JNK, NF-κB (via HDAC3 Ser374), and NRF2 pathways, and controls cytokinetic abscission by phosphorylating histone H2B (S14) and the severing enzyme spastin (S268) at the midbody [PMID:20307497, PMID:21602882, PMID:22658722, PMID:23871434, PMID:31284535, PMID:34244427]. Through these activities HIPK2 functions in neuronal survival and development and is a driver of organ fibrosis and pathological cardiac remodeling [PMID:15492043, PMID:17159989, PMID:22406746, PMID:36182775].","teleology":[{"year":1999,"claim":"Established HIPK2 as a SUMO-modified nuclear-speckle protein, defining its subnuclear localization machinery before any catalytic function was known.","evidence":"Yeast two-hybrid with mUBC9, co-IP, and localization in cells","pmids":["10535925"],"confidence":"High","gaps":["Functional consequence of SUMOylation not resolved","No link to kinase activity established at this stage"]},{"year":2000,"claim":"Placed HIPK2 in the DYRK kinase subfamily and showed a conserved catalytic lysine is essential, defining it as a bona fide kinase.","evidence":"Sequence alignment and kinase-dead catalytic-lysine mutant assay","pmids":["11120354"],"confidence":"Medium","gaps":["No physiological substrate identified","Activation mechanism unknown"]},{"year":2001,"claim":"Connected HIPK2 to the p53 pathway and cell-cycle control, showing it stabilizes p53 and lowers MDM2 in a kinase-dependent manner.","evidence":"Overexpression, reporter assays, kinase-dead mutant, and flow cytometry; in vitro HMGI(Y) phosphorylation","pmids":["11532197","11593421"],"confidence":"Medium","gaps":["Direct p53 phosphosite not yet identified","Mechanism of MDM2 reduction unresolved"]},{"year":2002,"claim":"Identified HIPK2 as a cofactor of p53-family transcription factors, linking it to nuclear-body-localized apoptotic transcription.","evidence":"Yeast two-hybrid, GST pulldown, co-IP, confocal microscopy, reporter and FACS assays with p73/p53; RanBPM interaction","pmids":["11925430","12220523"],"confidence":"High","gaps":["RanBPM interaction has no functional follow-up","Kinase-substrate relationship with p73 not defined"]},{"year":2003,"claim":"Defined PML nuclear bodies and Daxx as the platform for HIPK2 apoptotic signaling, showing PML is required for p53 Ser46 phosphorylation and HIPK2 activates JNK via Daxx in TGF-β apoptosis.","evidence":"Immunofluorescence, PML-knockout fibroblasts, co-IP, in vitro kinase assay, siRNA, JNK/apoptosis assays; TP53INP1 cooperation","pmids":["12907596","14678985","12851404","12565818"],"confidence":"High","gaps":["PML isoform recruitment determinants only partly mapped","Direct Daxx phosphosite not defined"]},{"year":2004,"claim":"Identified Axin as a scaffold that stimulates HIPK2-mediated p53 Ser46 phosphorylation and established HIPK2 in Wnt-linked transcription factor control (NLK/c-Myb, Brn3a, HMGA1).","evidence":"Co-IP, siRNA, kinase-dead and domain mutants, reporter and apoptosis assays, HIPK2-knockout mice with neuronal phenotypes","pmids":["15526030","15082531","15492043","14990717"],"confidence":"High","gaps":["How Axin relieves the putative autoinhibitory domain unresolved","In vivo relevance of c-Myb axis not tested in mammals"]},{"year":2005,"claim":"Showed HIPK2 SUMOylation is phosphorylation-dependent and functionally selective, fine-tuning interactions (Groucho, JNK) and identified MDM2 as both substrate and target, and PCAF cooperation for p21 induction.","evidence":"In vitro SUMOylation/desumoylation, kinase-dead mutants, ChIP, reporter assays, SuPr-1 and SENP1 analyses; in vitro MDM2 kinase assay","pmids":["15958389","15896780","15897882","16212962","16253240"],"confidence":"High","gaps":["MDM2 phosphosite not mapped","Reciprocal regulation of SUMO and ubiquitin pathways not integrated"]},{"year":2006,"claim":"Demonstrated HIPK2 as a transcriptional kinase activating AML1/p300 acetyltransferase activity and as essential for TGF-β-Smad survival of dopamine neurons, established with genetic knockouts.","evidence":"Co-IP, in vitro kinase assay, HAT assay, Hipk1/2 double-knockout and Hipk2-knockout mice with Smad interaction","pmids":["16917507","17159989"],"confidence":"High","gaps":["Direct Smad phosphorylation not demonstrated","AML1/p300 phosphosites not all mapped"]},{"year":2007,"claim":"Established the abundance-based apoptotic switch: MDM2 degrades HIPK2 to enforce growth arrest, while HIPK2 represses Wnt/LEF1 targets via CtBP, with Daxx refining p53 target selection.","evidence":"Degradation-resistant HIPK2 mutant, MDM2 overexpression, siRNA, YH-domain deletion, HIPK2-knockout mice, skin carcinogenesis model","pmids":["17349959","17666529","17210684"],"confidence":"High","gaps":["Threshold setting the arrest-versus-apoptosis decision not quantified","CtBP recruitment determinants partly mapped"]},{"year":2008,"claim":"Defined Siah-1 and Siah2 as the core E3 ligases controlling HIPK2 stability and showed DNA damage (ATM/ATR-Siah-1 Ser19) and hypoxia reciprocally regulate this destruction.","evidence":"Co-IP, ubiquitination assays, siRNA, ATM/ATR inhibition, Siah2-knockout cells, phosphosite mapping; PML/SCF(Fbx3) protection; ZBTB4 substrate identification","pmids":["18536714","19043406","18809579","19448668"],"confidence":"High","gaps":["Integration of multiple competing ligases not resolved","ZBTB4 phosphosite not mapped"]},{"year":2010,"claim":"Extended HIPK2 substrate range to direct β-catenin Ser33/37 phosphorylation (Wnt repression), ATF1 (antioxidant gene control), and refined SUMO/SIM-based PML targeting.","evidence":"In vitro kinase assays, mutagenesis, siRNA, reporter assays, HIPK2-null MEFs, Xenopus embryo and DCAF7/Han11 scaffold studies","pmids":["20307497","20980392","21145359","20940704"],"confidence":"High","gaps":["Priming-independent β-catenin recognition mechanism not structurally explained","Han11 scaffold stoichiometry undefined"]},{"year":2011,"claim":"Identified ΔNp63α (T397) as a degradation substrate linking HIPK2 to chemosensitivity, and expanded the stability network (Zyxin, HIF-1α) controlling HIPK2-dependent p53 Ser46 signaling.","evidence":"In vitro kinase assay, site mutagenesis, siRNA, cell survival assays; co-IP and dimerization assays for Zyxin/Siah-1; HIF-1α perturbations","pmids":["21602882","21248071","21248371"],"confidence":"High","gaps":["In vivo ΔNp63α axis not tested in mice","HIF-1α-HIPK2 degradation lacks ligase identity"]},{"year":2012,"claim":"Revealed a non-transcriptional role in cytokinesis through histone H2B Ser14 phosphorylation at the midbody and established HIPK2 as a pathway-integrating driver of organ fibrosis.","evidence":"In vitro kinase assay, HIPK2 knockout/RNAi, phosphomimetic H2B-S14D rescue, live imaging; Hipk2-knockout mice in multiple kidney fibrosis models","pmids":["22658722","22406746"],"confidence":"High","gaps":["How H2B-S14P drives abscission mechanically unresolved","Relative contribution of p53/TGF-β/Wnt arms to fibrosis not dissected"]},{"year":2013,"claim":"Defined the activation mechanism (cis-autophosphorylation of Y354/S357 and Thr880/Ser882 creating a Pin1 docking signal) and added WIP1 as a substrate plus scaffold/upstream regulators (Han11, Src, TAK1-Y361).","evidence":"In vitro autophosphorylation and kinase assays, mutagenesis, ubiquitination assays, zebrafish models, knockout mice, MS phosphosite mapping, co-IP","pmids":["23000554","24145406","23485397","23871434","20940704","24196445","23565059"],"confidence":"High","gaps":["How tyrosine autophosphorylation switches to S/T specificity not fully explained","Multiple upstream kinase inputs not integrated into one model"]},{"year":2014,"claim":"Added XAF1 as a Siah2 antagonist stabilizing HIPK2, and uncovered a kinase-independent role supporting Dvl via PP1c, embedding HIPK2 in both positive and negative Wnt regulation.","evidence":"Co-IP, ubiquitination assays, domain mutants, p53 phosphorylation assays; PP1c/Dvl co-IP, ubiquitination, zebrafish Wnt assays","pmids":["25313037","25159144"],"confidence":"High","gaps":["Reconciliation of HIPK2 as both β-catenin-degrading and Dvl-stabilizing unresolved","XAF1 regulation upstream not defined"]},{"year":2015,"claim":"Showed HIPK2 phosphorylates SIRT1 (Ser682) to disrupt the SIRT1-AROS complex and permit p53 acetylation, mechanistically linking HIPK2 to acetylation-dependent apoptotic gene expression.","evidence":"In vitro kinase assay, SIRT1 activity assay, co-IP, ChIP, PML knockdown","pmids":["26113041"],"confidence":"High","gaps":["Selectivity over SIRT1's many substrates not addressed","In vivo SIRT1-Ser682 relevance untested"]},{"year":2016,"claim":"Identified ER stress as an activating input (Ser359/Thr360 activation-loop phosphorylation) driving IRE1α-ASK1-JNK death, with disease relevance in ALS, and extended fibrosis/diabetic nephropathy roles.","evidence":"Phospho-specific antibodies, HIPK2-knockout mice in SOD1G93A ALS model, kinase assays; siRNA and diabetic mouse model for MeCP2/miR-25; DCAF7-E1A adaptor study","pmids":["27321923","27941951","27307198"],"confidence":"High","gaps":["Upstream kinase phosphorylating the activation loop under ER stress unidentified","MeCP2 phosphosite not mapped"]},{"year":2017,"claim":"Established a bidirectional HIPK2-NRF2 regulatory loop, placing HIPK2 within antioxidant/redox transcriptional control.","evidence":"ChIP identifying NRF2 binding site, reporter assays, gain/loss-of-function, HIPK2-knockout mice","pmids":["28692050"],"confidence":"Medium","gaps":["Whether HIPK2 directly phosphorylates NRF2 not established","Physiological trigger of the loop undefined"]},{"year":2018,"claim":"Linked HIPK2-JNK-c-Jun signaling to transcriptional repression of NMDA receptor subunit genes, extending its role in neuronal signaling and survival.","evidence":"Hipk2-knockout mice, transcriptomics, JNK assays, synaptic fractionation, electrophysiology","pmids":["29581378"],"confidence":"High","gaps":["Direct transcriptional targets of HIPK2 vs c-Jun not separated","Mechanism of subunit-selective repression unclear"]},{"year":2019,"claim":"Provided the active-conformation crystal structure and a second cytokinetic substrate (spastin Ser268), and identified STAT3-driven HIPK2 transcription in kidney injury.","evidence":"X-ray crystallography at 2.2 Å with CX-4945; in vitro kinase assay, phosphomimetic/non-phosphorylatable spastin mutants, abscission assays; ChIP for STAT3","pmids":["31341017","31284535","31131063"],"confidence":"High","gaps":["Structure of full-length or substrate-bound HIPK2 lacking","Coordination of H2B and spastin phosphorylation at midbody not integrated"]},{"year":2021,"claim":"Defined HIPK2-HDAC3 (Ser374) suppression of NF-κB inflammation and an ATM-SPOP non-degradative ubiquitination axis driving HP1γ phosphorylation in DNA repair, plus cardiac apoptosis roles.","evidence":"In vitro kinase and HDAC3 activity assays, knockout mice, sepsis models; co-IP, ubiquitination, SPOP mutants, ChIP; HIPK2-knockout/inhibitor MI models","pmids":["34244427","34133717","34837851"],"confidence":"High","gaps":["How non-degradative ubiquitination alters HIPK2 catalysis unresolved","Tissue-specific selectivity of HDAC3 vs other substrates undefined"]},{"year":2022,"claim":"Mapped HIPK2 effectors (EGR3/CLEC4D via ERK1/2-CREB; Smad3) in pathological cardiac remodeling, supporting HIPK2 inhibition as a cardioprotective strategy.","evidence":"HIPK2-knockout mice, pharmacological inhibitors, microarray, siRNA rescue, TAC model","pmids":["36182775"],"confidence":"Medium","gaps":["Whether EGR3/CLEC4D are direct HIPK2 transcriptional outputs unclear","Cell-type-specific kinase substrates in heart not defined"]},{"year":null,"claim":"How HIPK2 integrates its many competing upstream regulators and broad substrate repertoire into context-specific decisions (survival vs apoptosis, transcriptional vs cytokinetic) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of substrate- or scaffold-bound HIPK2","No systematic map of which inputs dominate in each tissue","Quantitative model of the stability-based apoptotic threshold lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[31,34,37,42,48,55,57]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,39,41]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,23,45]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[37]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[0,32]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[41,44]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,10,21,34,49]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[25,42,58]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,20,31,45,57]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[37,55]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,19,23,52]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[25,26,27,40]}],"complexes":[],"partners":["TP53","PML","DAXX","AXIN1","SIAH1","SIAH2","MDM2","PIN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H2X6","full_name":"Homeodomain-interacting protein kinase 2","aliases":[],"length_aa":1198,"mass_kda":131.0,"function":"Serine/threonine-protein kinase involved in transcription regulation, p53/TP53-mediated cellular apoptosis and regulation of the cell cycle. Acts as a corepressor of several transcription factors, including SMAD1 and POU4F1/Brn3a and probably NK homeodomain transcription factors. Phosphorylates PDX1, ATF1, PML, p53/TP53, CREB1, CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1, ZBTB4 and DAZAP2. Inhibits cell growth and promotes apoptosis through the activation of p53/TP53 both at the transcription level and at the protein level (by phosphorylation and indirect acetylation). The phosphorylation of p53/TP53 may be mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in the response to hypoxia by acting as a transcriptional co-suppressor of HIF1A. Mediates transcriptional activation of TP73. In response to TGFB, cooperates with DAXX to activate JNK. Negative regulator through phosphorylation and subsequent proteasomal degradation of CTNNB1 and the antiapoptotic factor CTBP1. In the Wnt/beta-catenin signaling pathway acts as an intermediate kinase between MAP3K7/TAK1 and NLK to promote the proteasomal degradation of MYB. Phosphorylates CBX4 upon DNA damage and promotes its E3 SUMO-protein ligase activity. Activates CREB1 and ATF1 transcription factors by phosphorylation in response to genotoxic stress. In response to DNA damage, stabilizes PML by phosphorylation. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation. Promotes angiogenesis, and is involved in erythroid differentiation, especially during fetal liver erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates EP300 transcription regulation activity. Triggers ZBTB4 protein degradation in response to DNA damage. In response to DNA damage, phosphorylates DAZAP2 which localizes DAZAP2 to the nucleus, reduces interaction of DAZAP2 with HIPK2 and prevents DAZAP2-dependent ubiquitination of HIPK2 by E3 ubiquitin-protein ligase SIAH1 and subsequent proteasomal degradation (PubMed:33591310). Modulates HMGA1 DNA-binding affinity. In response to high glucose, triggers phosphorylation-mediated subnuclear localization shifting of PDX1. Involved in the regulation of eye size, lens formation and retinal lamination during late embryogenesis","subcellular_location":"Nucleus, PML body; Cytoplasm; Cytoplasm, Stress granule","url":"https://www.uniprot.org/uniprotkb/Q9H2X6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HIPK2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":77,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HIPK2","total_profiled":1310},"omim":[{"mim_id":"610900","title":"CHARGED MULTIVESICULAR BODY PROTEIN 5; CHMP5","url":"https://www.omim.org/entry/610900"},{"mim_id":"610897","title":"CHARGED MULTIVESICULAR BODY PROTEIN 4B; CHMP4B","url":"https://www.omim.org/entry/610897"},{"mim_id":"607358","title":"AUTOIMMUNE REGULATOR; AIRE","url":"https://www.omim.org/entry/607358"},{"mim_id":"606868","title":"HOMEODOMAIN-INTERACTING PROTEIN KINASE 2; HIPK2","url":"https://www.omim.org/entry/606868"},{"mim_id":"605658","title":"INTERLEUKIN 25; IL25","url":"https://www.omim.org/entry/605658"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":146.1}],"url":"https://www.proteinatlas.org/search/HIPK2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9H2X6","domains":[{"cath_id":"3.30.200.20","chopping":"184-280","consensus_level":"medium","plddt":91.1444,"start":184,"end":280},{"cath_id":"1.10.510.10","chopping":"281-550","consensus_level":"high","plddt":94.792,"start":281,"end":550}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H2X6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H2X6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H2X6-F1-predicted_aligned_error_v6.png","plddt_mean":52.41},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HIPK2","jax_strain_url":"https://www.jax.org/strain/search?query=HIPK2"},"sequence":{"accession":"Q9H2X6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H2X6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H2X6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H2X6"}},"corpus_meta":[{"pmid":"28786753","id":"PMC_28786753","title":"Circular RNA HIPK2 regulates astrocyte activation via cooperation of autophagy and ER stress by targeting MIR124-2HG.","date":"2017","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/28786753","citation_count":224,"is_preprint":false},{"pmid":"18536714","id":"PMC_18536714","title":"Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18536714","citation_count":167,"is_preprint":false},{"pmid":"17349959","id":"PMC_17349959","title":"MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17349959","citation_count":154,"is_preprint":false},{"pmid":"15082531","id":"PMC_15082531","title":"Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15082531","citation_count":146,"is_preprint":false},{"pmid":"10535925","id":"PMC_10535925","title":"Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10535925","citation_count":142,"is_preprint":false},{"pmid":"15526030","id":"PMC_15526030","title":"Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15526030","citation_count":140,"is_preprint":false},{"pmid":"12851404","id":"PMC_12851404","title":"TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12851404","citation_count":134,"is_preprint":false},{"pmid":"22406746","id":"PMC_22406746","title":"A systems approach identifies HIPK2 as a key regulator of kidney fibrosis.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22406746","citation_count":129,"is_preprint":false},{"pmid":"14678985","id":"PMC_14678985","title":"HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14678985","citation_count":126,"is_preprint":false},{"pmid":"17666529","id":"PMC_17666529","title":"HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17666529","citation_count":118,"is_preprint":false},{"pmid":"20514025","id":"PMC_20514025","title":"Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20514025","citation_count":117,"is_preprint":false},{"pmid":"12907596","id":"PMC_12907596","title":"PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12907596","citation_count":117,"is_preprint":false},{"pmid":"19043406","id":"PMC_19043406","title":"An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19043406","citation_count":115,"is_preprint":false},{"pmid":"17245128","id":"PMC_17245128","title":"HIPK2: a versatile switchboard regulating the transcription machinery and cell death.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17245128","citation_count":114,"is_preprint":false},{"pmid":"16917507","id":"PMC_16917507","title":"Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16917507","citation_count":114,"is_preprint":false},{"pmid":"17159989","id":"PMC_17159989","title":"Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons.","date":"2006","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17159989","citation_count":113,"is_preprint":false},{"pmid":"17713576","id":"PMC_17713576","title":"HIPK2: a multitalented partner for transcription factors in DNA damage response and development.","date":"2007","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/17713576","citation_count":109,"is_preprint":false},{"pmid":"16537918","id":"PMC_16537918","title":"Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16537918","citation_count":93,"is_preprint":false},{"pmid":"19794125","id":"PMC_19794125","title":"Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.","date":"2009","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19794125","citation_count":93,"is_preprint":false},{"pmid":"15492043","id":"PMC_15492043","title":"Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15492043","citation_count":85,"is_preprint":false},{"pmid":"17210684","id":"PMC_17210684","title":"Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17210684","citation_count":85,"is_preprint":false},{"pmid":"19788416","id":"PMC_19788416","title":"Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling - roles of p53, p73 and HIPK2.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19788416","citation_count":81,"is_preprint":false},{"pmid":"11593421","id":"PMC_11593421","title":"High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11593421","citation_count":79,"is_preprint":false},{"pmid":"19828042","id":"PMC_19828042","title":"HIPK2 modulates p53 activity towards pro-apoptotic transcription.","date":"2009","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19828042","citation_count":78,"is_preprint":false},{"pmid":"22889244","id":"PMC_22889244","title":"Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.","date":"2012","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/22889244","citation_count":76,"is_preprint":false},{"pmid":"31131063","id":"PMC_31131063","title":"EGFR drives the progression of AKI to CKD through HIPK2 overexpression.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31131063","citation_count":76,"is_preprint":false},{"pmid":"23169233","id":"PMC_23169233","title":"HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis.","date":"2012","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23169233","citation_count":74,"is_preprint":false},{"pmid":"27321923","id":"PMC_27321923","title":"Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis.","date":"2016","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/27321923","citation_count":73,"is_preprint":false},{"pmid":"11925430","id":"PMC_11925430","title":"Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11925430","citation_count":73,"is_preprint":false},{"pmid":"18809579","id":"PMC_18809579","title":"PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18809579","citation_count":73,"is_preprint":false},{"pmid":"28692050","id":"PMC_28692050","title":"Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28692050","citation_count":72,"is_preprint":false},{"pmid":"18974774","id":"PMC_18974774","title":"How cells switch HIPK2 on and off.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/18974774","citation_count":63,"is_preprint":false},{"pmid":"26113041","id":"PMC_26113041","title":"HIPK2 restricts SIRT1 activity upon severe DNA damage by a phosphorylation-controlled mechanism.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26113041","citation_count":61,"is_preprint":false},{"pmid":"34244427","id":"PMC_34244427","title":"HIPK2 phosphorylates HDAC3 for NF-κB acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34244427","citation_count":61,"is_preprint":false},{"pmid":"15897882","id":"PMC_15897882","title":"HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15897882","citation_count":61,"is_preprint":false},{"pmid":"25313037","id":"PMC_25313037","title":"XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25313037","citation_count":61,"is_preprint":false},{"pmid":"23000554","id":"PMC_23000554","title":"HIPK2 kinase activity depends on cis-autophosphorylation of its activation loop.","date":"2012","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23000554","citation_count":58,"is_preprint":false},{"pmid":"15122315","id":"PMC_15122315","title":"HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15122315","citation_count":58,"is_preprint":false},{"pmid":"23871434","id":"PMC_23871434","title":"WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation.","date":"2013","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23871434","citation_count":57,"is_preprint":false},{"pmid":"18996371","id":"PMC_18996371","title":"Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18996371","citation_count":55,"is_preprint":false},{"pmid":"21698151","id":"PMC_21698151","title":"The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21698151","citation_count":54,"is_preprint":false},{"pmid":"22110707","id":"PMC_22110707","title":"Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22110707","citation_count":54,"is_preprint":false},{"pmid":"25282590","id":"PMC_25282590","title":"Verbascoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25282590","citation_count":52,"is_preprint":false},{"pmid":"34321461","id":"PMC_34321461","title":"Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34321461","citation_count":52,"is_preprint":false},{"pmid":"22658722","id":"PMC_22658722","title":"HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658722","citation_count":51,"is_preprint":false},{"pmid":"20940704","id":"PMC_20940704","title":"The WD40-repeat protein Han11 functions as a scaffold protein to control HIPK2 and MEKK1 kinase functions.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20940704","citation_count":51,"is_preprint":false},{"pmid":"32062357","id":"PMC_32062357","title":"Silencing of circular RNA HIPK2 in neural stem cells enhances functional recovery following ischaemic stroke.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32062357","citation_count":51,"is_preprint":false},{"pmid":"27307198","id":"PMC_27307198","title":"The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27307198","citation_count":50,"is_preprint":false},{"pmid":"23565059","id":"PMC_23565059","title":"Transcriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-β-TAK1-dependent mechanism.","date":"2013","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/23565059","citation_count":49,"is_preprint":false},{"pmid":"20876941","id":"PMC_20876941","title":"Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?","date":"2010","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/20876941","citation_count":47,"is_preprint":false},{"pmid":"21248371","id":"PMC_21248371","title":"HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation.","date":"2011","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/21248371","citation_count":47,"is_preprint":false},{"pmid":"34837851","id":"PMC_34837851","title":"Exercise downregulates HIPK2 and HIPK2 inhibition protects against myocardial infarction.","date":"2021","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/34837851","citation_count":45,"is_preprint":false},{"pmid":"24145406","id":"PMC_24145406","title":"Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24145406","citation_count":45,"is_preprint":false},{"pmid":"23485397","id":"PMC_23485397","title":"HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23485397","citation_count":45,"is_preprint":false},{"pmid":"20234185","id":"PMC_20234185","title":"HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20234185","citation_count":45,"is_preprint":false},{"pmid":"15958389","id":"PMC_15958389","title":"Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15958389","citation_count":44,"is_preprint":false},{"pmid":"27941951","id":"PMC_27941951","title":"Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27941951","citation_count":44,"is_preprint":false},{"pmid":"21248071","id":"PMC_21248071","title":"Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21248071","citation_count":44,"is_preprint":false},{"pmid":"21602882","id":"PMC_21602882","title":"HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21602882","citation_count":43,"is_preprint":false},{"pmid":"28107201","id":"PMC_28107201","title":"Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28107201","citation_count":42,"is_preprint":false},{"pmid":"23616089","id":"PMC_23616089","title":"Posttranslational modifications regulate HIPK2, a driver of proliferative diseases.","date":"2013","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/23616089","citation_count":41,"is_preprint":false},{"pmid":"30796178","id":"PMC_30796178","title":"The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30796178","citation_count":40,"is_preprint":false},{"pmid":"16253240","id":"PMC_16253240","title":"Desumoylation of homeodomain-interacting protein kinase 2 (HIPK2) through the cytoplasmic-nuclear shuttling of the SUMO-specific protease SENP1.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16253240","citation_count":40,"is_preprint":false},{"pmid":"21192925","id":"PMC_21192925","title":"Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21192925","citation_count":40,"is_preprint":false},{"pmid":"11120354","id":"PMC_11120354","title":"Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34.","date":"2000","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/11120354","citation_count":40,"is_preprint":false},{"pmid":"12565818","id":"PMC_12565818","title":"The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12565818","citation_count":39,"is_preprint":false},{"pmid":"36182775","id":"PMC_36182775","title":"Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling.","date":"2022","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/36182775","citation_count":38,"is_preprint":false},{"pmid":"29793420","id":"PMC_29793420","title":"Update on the Regulation of HIPK1, HIPK2 and HIPK3 Protein Kinases by microRNAs.","date":"2018","source":"MicroRNA (Shariqah, United Arab Emirates)","url":"https://pubmed.ncbi.nlm.nih.gov/29793420","citation_count":37,"is_preprint":false},{"pmid":"30154452","id":"PMC_30154452","title":"Overexpression of homeodomain-interacting protein kinase 2 (HIPK2) attenuates sepsis-mediated liver injury by restoring autophagy.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30154452","citation_count":36,"is_preprint":false},{"pmid":"20307497","id":"PMC_20307497","title":"Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for phosphorylation and proteasomal degradation.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20307497","citation_count":36,"is_preprint":false},{"pmid":"21145359","id":"PMC_21145359","title":"Control of nuclear HIPK2 localization and function by a SUMO interaction motif.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21145359","citation_count":35,"is_preprint":false},{"pmid":"20980392","id":"PMC_20980392","title":"Transcriptional regulation of ferritin and antioxidant genes by HIPK2 under genotoxic stress.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/20980392","citation_count":35,"is_preprint":false},{"pmid":"26312158","id":"PMC_26312158","title":"Role of HIPK2 in kidney fibrosis.","date":"2014","source":"Kidney international supplements","url":"https://pubmed.ncbi.nlm.nih.gov/26312158","citation_count":34,"is_preprint":false},{"pmid":"24196445","id":"PMC_24196445","title":"Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/24196445","citation_count":34,"is_preprint":false},{"pmid":"37165721","id":"PMC_37165721","title":"Extracellular Vesicle-Conjugated Functional Matrix Hydrogels Prevent Senescence by Exosomal miR-3594-5p-Targeted HIPK2/p53 Pathway for Disc Regeneration.","date":"2023","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37165721","citation_count":34,"is_preprint":false},{"pmid":"34973299","id":"PMC_34973299","title":"MiR-221-3p targets HIPK2 to promote diabetic wound healing.","date":"2021","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/34973299","citation_count":33,"is_preprint":false},{"pmid":"19448668","id":"PMC_19448668","title":"The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19448668","citation_count":33,"is_preprint":false},{"pmid":"12220523","id":"PMC_12220523","title":"HIPK2 associates with RanBPM.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12220523","citation_count":33,"is_preprint":false},{"pmid":"19438900","id":"PMC_19438900","title":"HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage.","date":"2009","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/19438900","citation_count":31,"is_preprint":false},{"pmid":"24785298","id":"PMC_24785298","title":"Identification of Hipk2 as an essential regulator of white fat development.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24785298","citation_count":31,"is_preprint":false},{"pmid":"15896780","id":"PMC_15896780","title":"Differential interactions of the homeodomain-interacting protein kinase 2 (HIPK2) by phosphorylation-dependent sumoylation.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15896780","citation_count":31,"is_preprint":false},{"pmid":"11532197","id":"PMC_11532197","title":"HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels.","date":"2001","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11532197","citation_count":31,"is_preprint":false},{"pmid":"22236966","id":"PMC_22236966","title":"HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.","date":"2012","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22236966","citation_count":30,"is_preprint":false},{"pmid":"32034309","id":"PMC_32034309","title":"HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32034309","citation_count":30,"is_preprint":false},{"pmid":"34133717","id":"PMC_34133717","title":"Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/34133717","citation_count":30,"is_preprint":false},{"pmid":"27308327","id":"PMC_27308327","title":"HIPK2 modification code for cell death and survival.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308327","citation_count":29,"is_preprint":false},{"pmid":"33027196","id":"PMC_33027196","title":"Circ-HIPK2 Accelerates Cell Apoptosis and Autophagy in Myocardial Oxidative Injury by Sponging miR-485-5p and Targeting ATG101.","date":"2020","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33027196","citation_count":28,"is_preprint":false},{"pmid":"19250734","id":"PMC_19250734","title":"Stabilization of HIPK2 by escape from proteasomal degradation mediated by the E3 ubiquitin ligase Siah1.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19250734","citation_count":28,"is_preprint":false},{"pmid":"36241057","id":"PMC_36241057","title":"HIPK2 in cancer biology and therapy: Recent findings and future perspectives.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/36241057","citation_count":27,"is_preprint":false},{"pmid":"32641685","id":"PMC_32641685","title":"SPEN induces miR-4652-3p to target HIPK2 in nasopharyngeal carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32641685","citation_count":27,"is_preprint":false},{"pmid":"16212962","id":"PMC_16212962","title":"HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16212962","citation_count":26,"is_preprint":false},{"pmid":"25868975","id":"PMC_25868975","title":"HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25868975","citation_count":26,"is_preprint":false},{"pmid":"31414572","id":"PMC_31414572","title":"HIPK2 role in the tumor-host interaction: Impact on fibroblasts transdifferentiation CAF-like.","date":"2019","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/31414572","citation_count":26,"is_preprint":false},{"pmid":"17960875","id":"PMC_17960875","title":"Homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates HMGA1a at Ser-35, Thr-52, and Thr-77 and modulates its DNA binding affinity.","date":"2007","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/17960875","citation_count":25,"is_preprint":false},{"pmid":"14990717","id":"PMC_14990717","title":"US11 of herpes simplex virus type 1 interacts with HIPK2 and antagonizes HIPK2-induced cell growth arrest.","date":"2004","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/14990717","citation_count":24,"is_preprint":false},{"pmid":"24586573","id":"PMC_24586573","title":"Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2).","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24586573","citation_count":24,"is_preprint":false},{"pmid":"31284535","id":"PMC_31284535","title":"HIPK2 Phosphorylates the Microtubule-Severing Enzyme Spastin at S268 for Abscission.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31284535","citation_count":23,"is_preprint":false},{"pmid":"25159144","id":"PMC_25159144","title":"Hipk2 and PP1c cooperate to maintain Dvl protein levels required for Wnt signal transduction.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25159144","citation_count":23,"is_preprint":false},{"pmid":"29581378","id":"PMC_29581378","title":"HIPK2-Mediated Transcriptional Control of NMDA Receptor Subunit Expression Regulates Neuronal Survival and Cell Death.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29581378","citation_count":23,"is_preprint":false},{"pmid":"31341017","id":"PMC_31341017","title":"The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31341017","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49589,"output_tokens":14452,"usd":0.182774,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":26297,"output_tokens":7377,"usd":0.157955,"stage2_stop_reason":"end_turn"},"total_usd":0.340729,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"HIPK2 is covalently modified by SUMO-1 at nuclear speckles. HIPK2 contains a speckle-retention signal that interacts with the SUMO E2 conjugating enzyme mUBC9, and SUMO-1 modification correlates with HIPK2 localization to nuclear speckles (dots).\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, cell-based localization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and localization experiments with functional correlation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"10535925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HIPK2 is a member of the DYRK kinase subfamily; a conserved lysine residue in the kinase domain is essential for HIPK2 kinase function.\",\n      \"method\": \"Sequence alignment, kinase-dead mutant functional assay\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — mutagenesis of catalytic residue, single lab, single paper\",\n      \"pmids\": [\"11120354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HIPK2 interacts with HMGI(Y) proteins through its PEST domain and phosphorylates HMGI(Y) in vitro; HIPK2 overexpression induces G2/M cell cycle arrest.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assay, colony assay, flow cytometry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay plus co-IP plus functional assay, single lab\",\n      \"pmids\": [\"11593421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HIPK2 overexpression stabilizes p53 protein and decreases MDM2 protein levels (post-transcriptionally), thereby increasing p53 transcriptional activity; kinase-dead HIPK2 does not produce these effects.\",\n      \"method\": \"Overexpression, reporter assay, western blot, kinase-dead mutant\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead mutant controls and functional reporter assays, single lab\",\n      \"pmids\": [\"11532197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HIPK2 interacts with RanBPM in the nucleus; both wild-type and kinase-dead HIPK2 co-localize with RanBPM in defined nuclear structures.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, co-localization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP and localization, no functional follow-up, single lab\",\n      \"pmids\": [\"12220523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HIPK2 interacts with p73α via the oligomerization domain region (aa 812-907 of HIPK2), co-localizes with p73 and p53 in nuclear bodies, and potentiates p73/p53-induced transcriptional repression and apoptotic response to genotoxic drugs.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, confocal microscopy, reporter assay, FACS\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (GST pulldown, co-IP, reporter, FACS) in one study, single lab\",\n      \"pmids\": [\"11925430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Endogenous HIPK2 and HIPK3 reside in novel subnuclear HIPK domains distinct from PML-NBs; PML isoform IV (but not III) recruits HIPK2 to PML-NBs; PML is required for HIPK2-mediated p53 Ser46 phosphorylation and antiproliferative function.\",\n      \"method\": \"Immunofluorescence, confocal microscopy, PML-knockout fibroblasts, functional reporter assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PML-null cell experiments plus isoform-specific recruitment and functional readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"12907596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HIPK2 co-localizes with Daxx in PML nuclear bodies, interacts with Daxx in vitro and in vivo via its kinase domain, phosphorylates Daxx, and activates the JNK pathway (via Daxx-MKK4/MKK7) to potentiate TGF-β-induced apoptosis; RNAi knockdown of HIPK2 inhibits TGF-β-induced JNK activation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding, in vitro kinase assay, siRNA knockdown, JNK activation assay, apoptosis assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, in vitro kinase assay, RNAi knockdown with defined signaling readout, single lab, multiple methods\",\n      \"pmids\": [\"14678985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TP53INP1 isoforms physically interact with HIPK2 and p53, co-localize in PML nuclear bodies, and cooperate with HIPK2 to regulate p53 transcriptional activity on p21, mdm2, pig3, and bax promoters.\",\n      \"method\": \"Co-immunoprecipitation, confocal microscopy, reporter assay, overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP and functional reporter assays, single lab\",\n      \"pmids\": [\"12851404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HIPK2 (PKM) modifies PML nuclear body (ND10) structure through both its kinase domain and a SUMO-1 interaction motif, and alters post-translational modification of PML.\",\n      \"method\": \"Overexpression, immunofluorescence, western blot\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — kinase-dead and SIM mutant analyses with localization readout, single lab\",\n      \"pmids\": [\"12565818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Axin interacts with HIPK2 and forms a multimeric complex with p53; Axin stimulates HIPK2-mediated phosphorylation of p53 at Ser46, facilitating p53-dependent transcription and apoptosis. The Axin-binding region of HIPK2 acts as a putative autoinhibitory domain.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, kinase-dead mutant, reporter assay, apoptosis assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, siRNA knockdown, kinase-dead controls, multiple functional readouts, single lab\",\n      \"pmids\": [\"15526030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Wnt-1 signal activates a TAK1→HIPK2→NLK pathway that phosphorylates c-Myb at multiple sites through direct NLK-c-Myb interaction facilitated by HIPK2, leading to c-Myb ubiquitination and proteasomal degradation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, overexpression, ubiquitination assay, differentiation assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay, co-IP, functional degradation assay, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"15082531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"HIPK2 interacts with the POU-domain transcription factor Brn3a, promotes Brn3a DNA binding, but suppresses Brn3a-dependent transcription of brn3a, trkA, and bcl-xL; targeted deletion of HIPK2 increases TrkA and Bcl-xL expression and reduces apoptosis in trigeminal ganglion neurons.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, HIPK2 knockout mice, immunohistochemistry, neuronal survival assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, reporter assays, and genetic knockout with specific neuronal phenotypes, single lab, multiple methods\",\n      \"pmids\": [\"15492043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Herpes simplex virus US11 protein interacts with HIPK2 through the PEST domain of HIPK2, alters HIPK2 subcellular distribution, and protects cells from HIPK2-induced cell growth arrest.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, localization, growth assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP, domain mapping, and functional assay, single lab\",\n      \"pmids\": [\"14990717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HIPK2 is SUMO-1 modified at Lys25 in vitro and in vivo; this sumoylation is phosphorylation-dependent (kinase-dead HIPK2 is not efficiently sumoylated) and inhibits HIPK2-induced JNK activation and p53-independent antiproliferative function. SUMO protease SuPr-1 co-localizes with HIPK2 in PML nuclear bodies and deconjugates SUMO-1 from HIPK2.\",\n      \"method\": \"In vitro SUMOylation, co-immunoprecipitation, siRNA, reporter assay, kinase-dead mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of SUMOylation plus kinase-dead mutant and functional assays, single lab, multiple methods\",\n      \"pmids\": [\"15958389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HIPK2 depletion inhibits PCAF-mediated p53 acetylation and p53 binding to the p21Waf1 promoter following nonapoptotic DNA damage; HIPK2 cooperates with PCAF to selectively induce p53 transcriptional activity toward p21Waf1.\",\n      \"method\": \"siRNA knockdown, chromatin immunoprecipitation, reporter assay, western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and siRNA with functional reporter readout, single lab\",\n      \"pmids\": [\"15897882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Phosphorylation-dependent SUMO modification of HIPK2 at Lys25 differentially regulates its interactions: sumoylation disrupts interaction with Groucho corepressor and inhibits HIPK2 regulation of Groucho-mediated transcriptional repression, but does not affect p53-mediated transactivation.\",\n      \"method\": \"In vitro SUMOylation, co-immunoprecipitation, reporter assay, kinase-dead mutant\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro sumoylation and functional reporter assay, single lab\",\n      \"pmids\": [\"15896780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HIPK2 interacts with MDM2 in vitro and in vivo, phosphorylates MDM2 in vitro, and promotes MDM2 nuclear export and proteasomal degradation in a p53-independent manner; additionally, HIPK2-dependent p53 Ser46 phosphorylation suppresses MDM2 at the transcriptional level.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, western blot, subcellular fractionation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay and co-IP with siRNA validation, single lab, two orthogonal methods\",\n      \"pmids\": [\"16212962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SENP1 desumoylates HIPK2 both in vitro and in vivo; desumoylation of HIPK2 by SENP1 leads to dissociation of HIPK2 from nuclear bodies; SENP1 contains a nuclear export sequence regulating its cytoplasmic-nuclear shuttling which in turn controls HIPK2 desumoylation.\",\n      \"method\": \"In vitro desumoylation assay, co-immunoprecipitation, SENP1 mutant analysis, localization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro desumoylation reconstitution and functional localization assay, single lab\",\n      \"pmids\": [\"16253240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HIPK2 forms a complex with AML1 and p300, phosphorylates both AML1 and p300 to stimulate their transcriptional and histone acetyltransferase (HAT) activities; p300 phosphorylation is triggered by phosphorylated AML1 as well as by PU.1, c-MYB, c-JUN and c-FOS. In Hipk1/2 double-knockout mouse embryos, phosphorylation of AML1 and p300 is impaired.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, HAT activity assay, double-knockout mice\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay, co-IP, genetic knockout with biochemical readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"16917507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HIPK2 is required for TGFβ-mediated survival of midbrain dopamine neurons; HIPK2 function depends on its interaction with receptor-regulated Smads to activate TGFβ target genes; loss of HIPK2 causes selective dopamine neuron apoptosis during programmed cell death.\",\n      \"method\": \"Hipk2 knockout mice, TGFβ3 survival assay, Smad interaction studies\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout phenotype validated with biochemical Smad interaction, replicated in Tgfbeta3-null comparison, single lab\",\n      \"pmids\": [\"17159989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MDM2-mediated proteasomal degradation of HIPK2 prevents p53 Ser46 phosphorylation during cytostatic (non-severe) DNA damage; a degradation-resistant HIPK2 mutant converts growth arrest to apoptosis. p53 actively represses HIPK2 via MDM2 to inhibit the apoptotic pathway.\",\n      \"method\": \"Degradation-resistant HIPK2 mutant, MDM2 overexpression, siRNA, p53 Ser46 phosphorylation assay, apoptosis assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mutant and knockdown experiments with defined apoptotic readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"17349959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Daxx associates with the Axin/HIPK2/p53 complex; Axin-Daxx interaction is enhanced by UV irradiation, and Axin tethers Daxx to p53 to cooperate with HIPK2-mediated Ser46 phosphorylation and selectively activate PUMA expression.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, reporter assay, colony formation assay, cell death assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP plus siRNA with functional readout, single lab\",\n      \"pmids\": [\"17210684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HIPK2 suppresses LEF1/β-catenin-mediated transcriptional activation of cyclin D1 by recruiting the corepressor CtBP through its C-terminal YH domain; deletion of the YH domain abolishes CtBP recruitment and loss of HIPK2 expands the epidermal stem cell compartment.\",\n      \"method\": \"HIPK2 knockout mice, reporter assay, YH-domain deletion mutant, gene expression analysis, skin carcinogenesis model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout plus domain-deletion mutant plus reporter assay with specific phenotypic readout, single lab, multiple methods\",\n      \"pmids\": [\"17666529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HIPK2 phosphorylates HMGA1a at Ser-35, Thr-52, and Thr-77 (and HMGA1b at Thr-41 and Thr-66), reducing HMGA1a binding affinity to DNA; the site preference of HIPK2 differs from that of cdc2.\",\n      \"method\": \"In vitro kinase assay, mass spectrometry, electrophoretic mobility shift assay\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay with MS mapping and functional DNA-binding assay, single lab\",\n      \"pmids\": [\"17960875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HIPK2 is an unstable protein that interacts with E3 ubiquitin ligase Siah-1 in unstressed cells; Siah-1 knockdown increases HIPK2 stability, and Siah-1 promotes HIPK2 polyubiquitination and proteasomal degradation. DNA damage disrupts the HIPK2-Siah-1 complex via ATM/ATR-dependent phosphorylation of Siah-1 at Ser19, stabilizing HIPK2.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, ATM/ATR inhibitor, phosphorylation site mutant\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, ubiquitination assay, genetic and pharmacological perturbation with mechanistic site mapping, replicated across multiple assays\",\n      \"pmids\": [\"18536714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Under normoxia, HIPK2 phosphorylates Siah2 at Ser26, Ser28, and Ser68, weakening mutual binding and destabilizing Siah2. Hypoxia increases HIPK2/Siah2 interaction, enabling efficient HIPK2 polyubiquitylation and proteasomal degradation; hypoxia-induced HIPK2 elimination is reduced in Siah2-deficient cells.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, Siah2-knockout cells, hypoxia treatment, phosphorylation mapping\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, phosphorylation mapping, genetic (Siah2-KO) validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"19043406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PML protects HIPK2 and p300 from SCFFbx3-mediated proteasomal degradation; Fbx3 forms SCF(Fbx3) ubiquitin ligase that promotes ubiquitin-proteasome degradation of HIPK2; PML, Fbx3, and HIPK2 synergistically activate p53-induced transcription. The leukemia-associated PML-RARα induces HIPK2 degradation.\",\n      \"method\": \"Purification of PML complex, co-immunoprecipitation, ubiquitination assay, reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complex purification plus ubiquitination assay plus functional reporter, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18809579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HIPK2 phosphorylates the transcription factor ZBTB4, leading to its proteasomal degradation under normal growth conditions and upon DNA damage; kinase-deficient HIPK2 does not cause ZBTB4 degradation; the two proteins interact in vitro and colocalize in vivo.\",\n      \"method\": \"In vitro binding, co-immunoprecipitation, kinase-dead mutant, siRNA, western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro kinase assay and kinase-dead mutant with degradation readout, single lab\",\n      \"pmids\": [\"19448668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Siah1 is an E3 ubiquitin ligase for HIPK2, targeting it for poly-ubiquitination and proteasomal degradation; this degradation is blocked by MLK-3, EBV LMP-1, or DNA-damaging stimuli.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, DNA damage treatment, western blot\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP and ubiquitination assay, single lab, replicates finding from PMID 18536714\",\n      \"pmids\": [\"19250734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HIPK2 is a new kinase for ATF1, phosphorylating it at Ser198 (not Ser63); HIPK2 overrides ATF1-mediated repression of ferritin H and other antioxidant genes at the ARE in a kinase-activity-dependent manner; induction of antioxidant genes by genotoxic stress is impaired in HIPK2-null MEFs.\",\n      \"method\": \"In vitro kinase assay, HIPK2-null MEFs, reporter assay, RT-PCR\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay, knockout MEFs with gene expression readout, reporter assay, multiple methods, single lab\",\n      \"pmids\": [\"20980392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HIPK2 phosphorylates β-catenin at Ser33 and Ser37, targeting it for proteasomal degradation without requiring a priming kinase; HIPK2 knockdown increases β-catenin nuclear accumulation and Wnt target gene expression; co-injection of HIPK2 mRNA blocks β-catenin-induced axis duplication in Xenopus embryos.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, siRNA, reporter assay, Xenopus embryo assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, siRNA knockdown, and in vivo Xenopus rescue, single lab, multiple methods\",\n      \"pmids\": [\"20307497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HIPK2 contains a SUMO-interacting motif (SIM) that binds all three major SUMO isoforms non-covalently; SIM mutation prevents localization of HIPK2 to nuclear speckles and PML nuclear bodies, disrupts colocalization with Pc2, and alters HIPK2 functional activity.\",\n      \"method\": \"SIM point mutant analysis, co-immunoprecipitation, immunofluorescence, SUMO binding assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mutant analysis with localization and functional readouts, single lab\",\n      \"pmids\": [\"21145359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SIM-mediated HIPK2 recruitment to PML-IV nuclear bodies is required for HIPK2-mediated p53 Ser46 phosphorylation and induction of apoptosis; HIPK2 specifically co-localizes with PML-I and PML-IV, and HIPK2 SIM mutants fail to activate or phosphorylate p53.\",\n      \"method\": \"Mutational analysis, co-immunoprecipitation, immunofluorescence, colony formation assay, p53 phosphorylation assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — SIM mutant with localization and functional phosphorylation readout, single lab\",\n      \"pmids\": [\"21192925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HIPK2 phosphorylates ΔNp63α at Thr397, promoting its proteasomal degradation in response to DNA damage; the non-phosphorylatable ΔNp63α-T397A mutant is not degraded and confers chemoresistance.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, siRNA, western blot, cell survival assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with phosphorylation site mutagenesis and functional rescue experiment, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21602882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Zyxin stabilizes HIPK2 by interfering with Siah-1 dimerization; Zyxin co-localizes with HIPK2 at the cytoskeleton and nucleus, physically interacts with Siah-1, and its depletion accelerates HIPK2 proteasomal degradation and reduces DNA damage-induced p53 Ser46 phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, western blot, p53 phosphorylation assay, caspase activation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, mechanistic model with dimerization assay, siRNA with functional phosphorylation readout, single lab\",\n      \"pmids\": [\"21248071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HIF-1α upregulation induces proteasomal degradation of HIPK2, thereby antagonizing p53-mediated apoptosis; HIF-1α inhibition by siRNA, dominant-negative HIF-1α, or zinc re-establishes HIPK2 levels and p53-mediated chemosensitivity.\",\n      \"method\": \"siRNA knockdown, dominant-negative HIF-1α, zinc supplementation, western blot, apoptosis assay\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple perturbations converging on HIPK2 degradation, single lab\",\n      \"pmids\": [\"21248371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HIPK2 binds and phosphorylates histone H2B at S14 (H2B-S14P); HIPK2 and H2B co-localize at the midbody during cytokinesis; HIPK2 depletion causes loss of H2B-S14P at the midbody, cytokinesis failure, and tetra/polyploidization. Phosphomimetic H2B-S14D rescues cytokinesis in HIPK2-null cells.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, HIPK2 knockout/RNAi, phosphomimetic mutant rescue, live-cell imaging\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, genetic KO, phosphomimetic rescue, and localization, multiple orthogonal methods and replicated across approaches\",\n      \"pmids\": [\"22658722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HIPK2 is a key regulator of kidney fibrosis; it activates p53, TGF-β-Smad3, and Wnt-Notch pathways in renal tubular epithelial cells to drive apoptosis and EMT; HIPK2 knockout attenuates kidney fibrosis in multiple murine models; HIV-induced oxidative stress increases HIPK2 by inhibiting Siah1-mediated proteasomal degradation.\",\n      \"method\": \"Hipk2-knockout mice, siRNA knockdown, pathway activation assays, mouse fibrosis models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout in multiple fibrosis models with pathway-level mechanistic validation, replicated across multiple disease contexts\",\n      \"pmids\": [\"22406746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HIPK2 is heavily autophosphorylated; cis-autophosphorylation at Y354 and S357 in the activation loop is essential for kinase activity, substrate binding, and interaction with Pin1; HIPK2 activation-loop phosphorylation is required for its biological activity as regulator of gene expression and cell proliferation.\",\n      \"method\": \"In vitro kinase assay, phosphosite mutants, cis-autophosphorylation assay, reporter assay, cell proliferation assay\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of cis-autophosphorylation with mutagenesis and multiple functional assays, single lab\",\n      \"pmids\": [\"23000554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HIPK2 autophosphorylates at Thr880/Ser882 upon DNA damage; this autophosphorylation creates a binding signal for the phospho-specific isomerase Pin1, which stabilizes HIPK2 by inhibiting its polyubiquitination and modulating Siah-1-HIPK2 interaction; Pin1 is required for DNA damage-induced HIPK2 stabilization, p53 Ser46 phosphorylation, and apoptosis in zebrafish.\",\n      \"method\": \"Autophosphorylation assay, co-immunoprecipitation, ubiquitination assay, zebrafish in vivo model, site-directed mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro autophosphorylation reconstitution, Pin1 binding, ubiquitination, and in vivo zebrafish validation with mutagenesis, multiple methods and replicated in vivo\",\n      \"pmids\": [\"24145406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Autophosphorylation of HIPK2 at activation-loop Y354 is an autocatalytic event essential for S/T-kinase activity; prevention of Y354 phosphorylation by mutagenesis or purvalanol A reduces HIPK2 kinase activity, induces aberrant tyrosine-kinase activity in cis, and causes cytoplasmic relocalization of HIPK2.\",\n      \"method\": \"Site-directed mutagenesis, kinase inhibitor, in vitro kinase assay, subcellular localization\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis and inhibitor with in vitro kinase assay and localization readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23485397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HIPK2 identifies WIP1 phosphatase as a substrate, phosphorylating and targeting it for proteasomal degradation in unstressed cells; upon ionizing radiation, ATM-dependent AMPKα2-mediated HIPK2 phosphorylation dissociates WIP1 from HIPK2, allowing WIP1 stabilization and termination of ATM signaling.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, hipk2-knockout mice, γ-H2AX assay, cell cycle checkpoint analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, in vitro kinase assay, knockout mice with in vivo phenotype, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"23871434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Han11/DCAF7/WDR68 is a scaffold protein that directly binds HIPK2 and MEKK1, coupling these kinases together; Han11 controls the threshold, amplitude, and kinetics of HIPK2- and MEKK1-driven signaling; loss of Han11 lowers the threshold of HIPK2-triggered transcriptional responses.\",\n      \"method\": \"In vitro binding, co-immunoprecipitation, siRNA knockdown in C. elegans and human cells, reporter assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro direct binding, reciprocal co-IP, functional knockdown in two organisms, single lab, multiple methods\",\n      \"pmids\": [\"20940704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Src kinase phosphorylates HIPK2 at nine tyrosine residues (including Tyr354 in the kinase domain), increases HIPK2 half-life by interfering with Siah-1-mediated degradation, and redistributes HIPK2 from the nucleus to the cytoplasm, thereby decreasing drug-induced p53 Ser46 phosphorylation and apoptosis.\",\n      \"method\": \"Mass spectrometry, phosphorylation-specific antibody, co-immunoprecipitation, half-life assay, subcellular fractionation, apoptosis assay\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS phosphosite identification, co-IP, stability assay, localization and functional apoptosis readout, single lab\",\n      \"pmids\": [\"24196445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HIPK1 and HIPK2 are transcriptional corepressors that regulate TGF-β-dependent angiogenesis; TGF-β-TAK1 signaling activates HIPK2 by phosphorylating conserved Y-361 within the kinase domain; point mutation Y361A abolishes HIPK2 corepressor activity; the effect of HIPK2 is mediated through interaction with transcription factor MEF2C.\",\n      \"method\": \"Hipk1/2 knockout mice, siRNA knockdown in endothelial cells, reporter assay, Y361 mutant, co-immunoprecipitation\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout, reporter assay with specific mutant, co-IP for MEF2C interaction, multiple methods, single lab\",\n      \"pmids\": [\"23565059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"XAF1 blocks Siah2 interaction with and ubiquitination of HIPK2, thereby stabilizing HIPK2 and stimulating HIPK2-mediated Ser46 phosphorylation of p53; XAF1 physically interacts with Siah2 through its zinc finger domains 5 and 6.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA, p53 phosphorylation assay, ZF domain mutants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ubiquitination assay, and domain-specific mutants, single lab\",\n      \"pmids\": [\"25313037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hipk2 and PP1c cooperate to maintain Dvl protein levels; Hipk2 facilitates PP1c-mediated dephosphorylation of Dvl via its C-terminal domain, blocking Itch-mediated ubiquitination and degradation of phosphorylated Dvl; inhibition of Hipk2 or PP1c reduces Dvl levels and suppresses Wnt/β-catenin and Wnt/PCP signaling in cells and zebrafish.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA, zebrafish embryo assay, Wnt reporter assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, ubiquitination assay, and in vivo zebrafish validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"25159144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HIPK2 phosphorylates SIRT1 at Ser682 upon lethal DNA damage; this phosphorylation inhibits SIRT1 deacetylase activity by disrupting the SIRT1-AROS activator complex, promoting p53 acetylation and apoptotic target gene expression; SIRT1-HIPK2 co-localize at PML nuclear bodies, and PML depletion abrogates SIRT1 Ser682 phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, SIRT1 activity assay, siRNA, ChIP, PML-knockdown\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with identified substrate site, SIRT1 activity assay, co-IP, PML knockdown with defined phosphorylation readout, single lab, multiple methods\",\n      \"pmids\": [\"26113041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ER stress (induced by tunicamycin or SOD1G93A) activates HIPK2 by phosphorylating Ser359/Thr360 in its activation loop; activated HIPK2 promotes ER-stress-induced cell death via the IRE1α-ASK1-JNK pathway; loss of HIPK2 delays disease onset and reduces motor neuron death in SOD1G93A ALS mice.\",\n      \"method\": \"Phospho-specific antibody, HIPK2-knockout mice, kinase assay, in vivo ALS model, cell death assay\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — phospho-site identification, HIPK2-KO with in vivo phenotype in ALS model, IRE1α-ASK1-JNK pathway placement, single lab, multiple methods\",\n      \"pmids\": [\"27321923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HIPK2 phosphorylates MeCP2, and the resulting p-MeCP2 suppresses processing of miR-25, leading to elevated NOX4 in diabetic nephropathy; SIAH1 decreases in diabetic glomeruli, correlating with increased HIPK2 protein stability.\",\n      \"method\": \"siRNA knockdown, western blot, qRT-PCR, streptozotocin diabetic mouse model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA-based epistasis with defined molecular pathway, single lab, single mouse model\",\n      \"pmids\": [\"27941951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DCAF7/WDR68 serves as an adaptor for HIPK2 binding to the adenovirus E1A oncoprotein; DCAF7 is required for HIPK2-mediated hyperphosphorylation of E1A; DCAF7 binds HIPK2 via a conserved 12-amino acid motif; the closely related HIPK1 does not bind DCAF7.\",\n      \"method\": \"Immunoprecipitation, pulldown, DCAF7 motif mutant, overexpression phosphorylation assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, pulldown, and functional phosphorylation assay with motif mutants, single lab\",\n      \"pmids\": [\"27307198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HIPK2 is a direct transcriptional target of NRF2; a functional NRF2 binding site was identified in the HIPK2 gene locus; HIPK2 is also required for robust NRF2 responsiveness in cells and in vivo, establishing a bidirectional HIPK2-NRF2 regulatory loop.\",\n      \"method\": \"ChIP, reporter assay, gain-of-function, loss-of-function (HIPK2 KO mice), NRF2 target gene assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP identifies functional NRF2 binding site, KO mice validate requirement, gain/loss-of-function, single lab\",\n      \"pmids\": [\"28692050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HIPK2-JNK-c-Jun signaling suppresses transcription of Grin2a and Grin2c (encoding GluN2A and GluN2C NMDA receptor subunits); loss of HIPK2 decreases JNK-c-Jun signaling, derepresses GluN2A/GluN2C expression, and increases GluN2A/GluN2B ratio in synapse and mitochondria, activating the ERK-CREB prosurvival pathway.\",\n      \"method\": \"Hipk2-knockout mice, transcriptomic analysis, JNK activity assay, synaptic fractionation, electrophysiology\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with transcriptomic, biochemical, and synaptic pathway readouts, multiple methods, single lab\",\n      \"pmids\": [\"29581378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the HIPK2 kinase domain bound to CX-4945 at 2.2 Å reveals an active conformation stabilized by activation-loop phosphorylation; the CMGC-insert region and the αC-β4 loop insert adopt conformations unique among DYRK-family kinases; CX-4945 engages the active site in a hybrid CK2α/Pim1-like binding mode.\",\n      \"method\": \"X-ray crystallography at 2.2 Å\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with defined active conformation and inhibitor binding mode, replicated via structural analysis\",\n      \"pmids\": [\"31341017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HIPK2 binds and phosphorylates the microtubule-severing enzyme spastin at Ser268; midbody-localized spastin phosphorylation at S268 is HIPK2-dependent; non-phosphorylatable spastin-S268A fails to localize at the midbody and cannot rescue abscission defects in HIPK2-depleted cells; phosphomimetic spastin-S268D restores midbody localization and successful abscission.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, immunofluorescence, cytokinesis assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with site-specific mutagenesis, phosphomimetic rescue, and functional abscission readout, single lab, multiple methods\",\n      \"pmids\": [\"31284535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EGFR/STAT3 signaling drives HIPK2 expression in kidney tubular epithelial cells; ChIP analysis shows STAT3 directly binds the promoter region of HIPK2; HIPK2 silencing attenuates vancomycin-induced AKI-to-CKD progression.\",\n      \"method\": \"ChIP analysis, EGFR mutant mice, gefitinib treatment, HIPK2 siRNA, western blot\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP with STAT3 promoter binding plus genetic and pharmacological validation, single lab\",\n      \"pmids\": [\"31131063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIPK2 binds and phosphorylates HDAC3 at Ser374, inhibiting its deacetylase activity, thus preventing deacetylation of NF-κB p65 at Lys218 and suppressing NF-κB-driven inflammatory gene expression in macrophages.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, HDAC3 activity assay, site-directed mutagenesis, HIPK2 knockout mice, CLP and LPS models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with specific phosphosite, HDAC3 activity assay, genetic KO mice with in vivo sepsis model, multiple orthogonal methods\",\n      \"pmids\": [\"34244427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Upon DNA damage, ATM phosphorylates SPOP at Ser119, potentiating SPOP binding to HIPK2 and triggering non-degradative ubiquitination of HIPK2; this modification increases HIPK2-mediated phosphorylation of HP1γ, promoting HP1γ dissociation from H3K9me3 to initiate DNA damage repair; cancer-associated SPOP mutations abrogate this axis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, in vitro kinase assay, phospho-specific antibodies, SPOP mutants, ChIP\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, ubiquitination assay, phospho-mutant analysis, functional DNA-repair readout, single lab, multiple methods\",\n      \"pmids\": [\"34133717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIPK2 suppression attenuates cardiomyocyte apoptosis after myocardial infarction via decreasing p53 phosphorylation; miR-222 targets HIPK2 to mediate exercise-induced cardioprotection; protective effect of HIPK2 suppression is reversed by p53 activators.\",\n      \"method\": \"HIPK2-knockout mice, HIPK2 inhibitor, lentiviral knockdown, p53 activator rescue, OGD/R assay in hESC-CMs\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice plus inhibitor with in vivo MI model and p53 activator epistasis, single lab\",\n      \"pmids\": [\"34837851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HIPK2 inhibition protects against pathological cardiac remodeling by reducing EGR3 and CLEC4D expression via ERK1/2-CREB inhibition in cardiomyocytes, and by suppressing Smad3 phosphorylation in cardiac fibroblasts.\",\n      \"method\": \"HIPK2 knockout mice, pharmacological inhibitors, microarray, siRNA rescue (EGR3/CLEC4D/Smad3), TAC model\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice plus microarray-identified targets with rescue experiments, single lab, multiple methods\",\n      \"pmids\": [\"36182775\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HIPK2 is a nuclear serine/threonine (and dual-specificity) kinase that is activated by cis-autophosphorylation of its activation loop (Y354/S357) and by upstream kinases (ATM, ATR, TGF-β-TAK1), and whose stability is tightly regulated by competing ubiquitin E3 ligases (Siah-1, Siah2, MDM2, SCFFbx3) and stabilizing factors (Zyxin, XAF1, PML, Pin1); upon severe genotoxic or ER stress, HIPK2 phosphorylates p53 at Ser46 to drive apoptotic gene expression, phosphorylates and inhibits SIRT1 (Ser682) to permit p53 acetylation, phosphorylates and degrades the anti-apoptotic ΔNp63α (T397) and WIP1, and controls cytokinesis by phosphorylating histone H2B (S14) and the microtubule-severing enzyme spastin (S268) at the midbody; HIPK2 also represses Wnt/β-catenin signaling by directly phosphorylating β-catenin (Ser33/37) for proteasomal degradation, suppresses NF-κB-driven inflammation by phosphorylating HDAC3 (Ser374), and modulates TGF-β-Smad, JNK-c-Jun, and NRF2 pathways in a context-dependent manner, with its crystal structure showing an active DYRK-like kinase domain with a unique CMGC-insert conformation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HIPK2 is a nuclear DYRK-family serine/threonine kinase that acts as a stress-responsive signaling hub coupling genotoxic and ER stress to apoptotic gene expression, developmental transcriptional control, and cytokinesis [#1, #21, #37]. Its catalytic activity depends on cis-autophosphorylation of activation-loop residues Y354 and S357, which is required for substrate binding and for nuclear retention, and a crystal structure of the kinase domain confirms an active conformation with a CMGC-insert region structurally unique among DYRK kinases [#39, #41, #54]. HIPK2 localizes to subnuclear HIPK domains and is recruited to PML nuclear bodies through both covalent SUMO-1 modification at Lys25 and a non-covalent SUMO-interacting motif, and this PML/SUMO-dependent compartmentalization is required for HIPK2-mediated p53 Ser46 phosphorylation and apoptosis [#0, #6, #14, #32, #33]. The central pro-apoptotic output is phosphorylation of p53 at Ser46—potentiated by the Axin/Daxx scaffold and by inhibitory phosphorylation of SIRT1 (Ser682) that permits p53 acetylation—driving selective apoptotic and antioxidant target gene expression [#10, #22, #48]. HIPK2 stability is the principal switch governing this decision: in unstressed or growth states it is held low by E3 ligases Siah-1, Siah2, MDM2, and SCF(Fbx3), while DNA damage (via ATM/ATR), the stabilizers Zyxin, XAF1, PML, and Pin1, and oncogenic regulators (HIF-1\\u03b1, Src) tune its abundance to set the apoptotic threshold [#21, #25, #26, #27, #35, #40, #44, #46]. Beyond p53, HIPK2 directly phosphorylates and degrades anti-apoptotic \\u0394Np63\\u03b1 (T397) and the WIP1 phosphatase, represses Wnt/\\u03b2-catenin signaling by phosphorylating \\u03b2-catenin at Ser33/37 for degradation, modulates TGF-\\u03b2-Smad, JNK, NF-\\u03baB (via HDAC3 Ser374), and NRF2 pathways, and controls cytokinetic abscission by phosphorylating histone H2B (S14) and the severing enzyme spastin (S268) at the midbody [#31, #34, #37, #42, #55, #57]. Through these activities HIPK2 functions in neuronal survival and development and is a driver of organ fibrosis and pathological cardiac remodeling [#12, #20, #38, #60].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established HIPK2 as a SUMO-modified nuclear-speckle protein, defining its subnuclear localization machinery before any catalytic function was known.\",\n      \"evidence\": \"Yeast two-hybrid with mUBC9, co-IP, and localization in cells\",\n      \"pmids\": [\"10535925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of SUMOylation not resolved\", \"No link to kinase activity established at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placed HIPK2 in the DYRK kinase subfamily and showed a conserved catalytic lysine is essential, defining it as a bona fide kinase.\",\n      \"evidence\": \"Sequence alignment and kinase-dead catalytic-lysine mutant assay\",\n      \"pmids\": [\"11120354\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No physiological substrate identified\", \"Activation mechanism unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Connected HIPK2 to the p53 pathway and cell-cycle control, showing it stabilizes p53 and lowers MDM2 in a kinase-dependent manner.\",\n      \"evidence\": \"Overexpression, reporter assays, kinase-dead mutant, and flow cytometry; in vitro HMGI(Y) phosphorylation\",\n      \"pmids\": [\"11532197\", \"11593421\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct p53 phosphosite not yet identified\", \"Mechanism of MDM2 reduction unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified HIPK2 as a cofactor of p53-family transcription factors, linking it to nuclear-body-localized apoptotic transcription.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown, co-IP, confocal microscopy, reporter and FACS assays with p73/p53; RanBPM interaction\",\n      \"pmids\": [\"11925430\", \"12220523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RanBPM interaction has no functional follow-up\", \"Kinase-substrate relationship with p73 not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined PML nuclear bodies and Daxx as the platform for HIPK2 apoptotic signaling, showing PML is required for p53 Ser46 phosphorylation and HIPK2 activates JNK via Daxx in TGF-\\u03b2 apoptosis.\",\n      \"evidence\": \"Immunofluorescence, PML-knockout fibroblasts, co-IP, in vitro kinase assay, siRNA, JNK/apoptosis assays; TP53INP1 cooperation\",\n      \"pmids\": [\"12907596\", \"14678985\", \"12851404\", \"12565818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PML isoform recruitment determinants only partly mapped\", \"Direct Daxx phosphosite not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified Axin as a scaffold that stimulates HIPK2-mediated p53 Ser46 phosphorylation and established HIPK2 in Wnt-linked transcription factor control (NLK/c-Myb, Brn3a, HMGA1).\",\n      \"evidence\": \"Co-IP, siRNA, kinase-dead and domain mutants, reporter and apoptosis assays, HIPK2-knockout mice with neuronal phenotypes\",\n      \"pmids\": [\"15526030\", \"15082531\", \"15492043\", \"14990717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Axin relieves the putative autoinhibitory domain unresolved\", \"In vivo relevance of c-Myb axis not tested in mammals\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed HIPK2 SUMOylation is phosphorylation-dependent and functionally selective, fine-tuning interactions (Groucho, JNK) and identified MDM2 as both substrate and target, and PCAF cooperation for p21 induction.\",\n      \"evidence\": \"In vitro SUMOylation/desumoylation, kinase-dead mutants, ChIP, reporter assays, SuPr-1 and SENP1 analyses; in vitro MDM2 kinase assay\",\n      \"pmids\": [\"15958389\", \"15896780\", \"15897882\", \"16212962\", \"16253240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MDM2 phosphosite not mapped\", \"Reciprocal regulation of SUMO and ubiquitin pathways not integrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated HIPK2 as a transcriptional kinase activating AML1/p300 acetyltransferase activity and as essential for TGF-\\u03b2-Smad survival of dopamine neurons, established with genetic knockouts.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, HAT assay, Hipk1/2 double-knockout and Hipk2-knockout mice with Smad interaction\",\n      \"pmids\": [\"16917507\", \"17159989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Smad phosphorylation not demonstrated\", \"AML1/p300 phosphosites not all mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the abundance-based apoptotic switch: MDM2 degrades HIPK2 to enforce growth arrest, while HIPK2 represses Wnt/LEF1 targets via CtBP, with Daxx refining p53 target selection.\",\n      \"evidence\": \"Degradation-resistant HIPK2 mutant, MDM2 overexpression, siRNA, YH-domain deletion, HIPK2-knockout mice, skin carcinogenesis model\",\n      \"pmids\": [\"17349959\", \"17666529\", \"17210684\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold setting the arrest-versus-apoptosis decision not quantified\", \"CtBP recruitment determinants partly mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined Siah-1 and Siah2 as the core E3 ligases controlling HIPK2 stability and showed DNA damage (ATM/ATR-Siah-1 Ser19) and hypoxia reciprocally regulate this destruction.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, siRNA, ATM/ATR inhibition, Siah2-knockout cells, phosphosite mapping; PML/SCF(Fbx3) protection; ZBTB4 substrate identification\",\n      \"pmids\": [\"18536714\", \"19043406\", \"18809579\", \"19448668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of multiple competing ligases not resolved\", \"ZBTB4 phosphosite not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended HIPK2 substrate range to direct \\u03b2-catenin Ser33/37 phosphorylation (Wnt repression), ATF1 (antioxidant gene control), and refined SUMO/SIM-based PML targeting.\",\n      \"evidence\": \"In vitro kinase assays, mutagenesis, siRNA, reporter assays, HIPK2-null MEFs, Xenopus embryo and DCAF7/Han11 scaffold studies\",\n      \"pmids\": [\"20307497\", \"20980392\", \"21145359\", \"20940704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Priming-independent \\u03b2-catenin recognition mechanism not structurally explained\", \"Han11 scaffold stoichiometry undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified \\u0394Np63\\u03b1 (T397) as a degradation substrate linking HIPK2 to chemosensitivity, and expanded the stability network (Zyxin, HIF-1\\u03b1) controlling HIPK2-dependent p53 Ser46 signaling.\",\n      \"evidence\": \"In vitro kinase assay, site mutagenesis, siRNA, cell survival assays; co-IP and dimerization assays for Zyxin/Siah-1; HIF-1\\u03b1 perturbations\",\n      \"pmids\": [\"21602882\", \"21248071\", \"21248371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo \\u0394Np63\\u03b1 axis not tested in mice\", \"HIF-1\\u03b1-HIPK2 degradation lacks ligase identity\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed a non-transcriptional role in cytokinesis through histone H2B Ser14 phosphorylation at the midbody and established HIPK2 as a pathway-integrating driver of organ fibrosis.\",\n      \"evidence\": \"In vitro kinase assay, HIPK2 knockout/RNAi, phosphomimetic H2B-S14D rescue, live imaging; Hipk2-knockout mice in multiple kidney fibrosis models\",\n      \"pmids\": [\"22658722\", \"22406746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How H2B-S14P drives abscission mechanically unresolved\", \"Relative contribution of p53/TGF-\\u03b2/Wnt arms to fibrosis not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the activation mechanism (cis-autophosphorylation of Y354/S357 and Thr880/Ser882 creating a Pin1 docking signal) and added WIP1 as a substrate plus scaffold/upstream regulators (Han11, Src, TAK1-Y361).\",\n      \"evidence\": \"In vitro autophosphorylation and kinase assays, mutagenesis, ubiquitination assays, zebrafish models, knockout mice, MS phosphosite mapping, co-IP\",\n      \"pmids\": [\"23000554\", \"24145406\", \"23485397\", \"23871434\", \"20940704\", \"24196445\", \"23565059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How tyrosine autophosphorylation switches to S/T specificity not fully explained\", \"Multiple upstream kinase inputs not integrated into one model\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Added XAF1 as a Siah2 antagonist stabilizing HIPK2, and uncovered a kinase-independent role supporting Dvl via PP1c, embedding HIPK2 in both positive and negative Wnt regulation.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, domain mutants, p53 phosphorylation assays; PP1c/Dvl co-IP, ubiquitination, zebrafish Wnt assays\",\n      \"pmids\": [\"25313037\", \"25159144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation of HIPK2 as both \\u03b2-catenin-degrading and Dvl-stabilizing unresolved\", \"XAF1 regulation upstream not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed HIPK2 phosphorylates SIRT1 (Ser682) to disrupt the SIRT1-AROS complex and permit p53 acetylation, mechanistically linking HIPK2 to acetylation-dependent apoptotic gene expression.\",\n      \"evidence\": \"In vitro kinase assay, SIRT1 activity assay, co-IP, ChIP, PML knockdown\",\n      \"pmids\": [\"26113041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity over SIRT1's many substrates not addressed\", \"In vivo SIRT1-Ser682 relevance untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified ER stress as an activating input (Ser359/Thr360 activation-loop phosphorylation) driving IRE1\\u03b1-ASK1-JNK death, with disease relevance in ALS, and extended fibrosis/diabetic nephropathy roles.\",\n      \"evidence\": \"Phospho-specific antibodies, HIPK2-knockout mice in SOD1G93A ALS model, kinase assays; siRNA and diabetic mouse model for MeCP2/miR-25; DCAF7-E1A adaptor study\",\n      \"pmids\": [\"27321923\", \"27941951\", \"27307198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream kinase phosphorylating the activation loop under ER stress unidentified\", \"MeCP2 phosphosite not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established a bidirectional HIPK2-NRF2 regulatory loop, placing HIPK2 within antioxidant/redox transcriptional control.\",\n      \"evidence\": \"ChIP identifying NRF2 binding site, reporter assays, gain/loss-of-function, HIPK2-knockout mice\",\n      \"pmids\": [\"28692050\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HIPK2 directly phosphorylates NRF2 not established\", \"Physiological trigger of the loop undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked HIPK2-JNK-c-Jun signaling to transcriptional repression of NMDA receptor subunit genes, extending its role in neuronal signaling and survival.\",\n      \"evidence\": \"Hipk2-knockout mice, transcriptomics, JNK assays, synaptic fractionation, electrophysiology\",\n      \"pmids\": [\"29581378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of HIPK2 vs c-Jun not separated\", \"Mechanism of subunit-selective repression unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the active-conformation crystal structure and a second cytokinetic substrate (spastin Ser268), and identified STAT3-driven HIPK2 transcription in kidney injury.\",\n      \"evidence\": \"X-ray crystallography at 2.2 \\u00c5 with CX-4945; in vitro kinase assay, phosphomimetic/non-phosphorylatable spastin mutants, abscission assays; ChIP for STAT3\",\n      \"pmids\": [\"31341017\", \"31284535\", \"31131063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length or substrate-bound HIPK2 lacking\", \"Coordination of H2B and spastin phosphorylation at midbody not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined HIPK2-HDAC3 (Ser374) suppression of NF-\\u03baB inflammation and an ATM-SPOP non-degradative ubiquitination axis driving HP1\\u03b3 phosphorylation in DNA repair, plus cardiac apoptosis roles.\",\n      \"evidence\": \"In vitro kinase and HDAC3 activity assays, knockout mice, sepsis models; co-IP, ubiquitination, SPOP mutants, ChIP; HIPK2-knockout/inhibitor MI models\",\n      \"pmids\": [\"34244427\", \"34133717\", \"34837851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How non-degradative ubiquitination alters HIPK2 catalysis unresolved\", \"Tissue-specific selectivity of HDAC3 vs other substrates undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapped HIPK2 effectors (EGR3/CLEC4D via ERK1/2-CREB; Smad3) in pathological cardiac remodeling, supporting HIPK2 inhibition as a cardioprotective strategy.\",\n      \"evidence\": \"HIPK2-knockout mice, pharmacological inhibitors, microarray, siRNA rescue, TAC model\",\n      \"pmids\": [\"36182775\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EGR3/CLEC4D are direct HIPK2 transcriptional outputs unclear\", \"Cell-type-specific kinase substrates in heart not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HIPK2 integrates its many competing upstream regulators and broad substrate repertoire into context-specific decisions (survival vs apoptosis, transcriptional vs cytokinetic) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of substrate- or scaffold-bound HIPK2\", \"No systematic map of which inputs dominate in each tissue\", \"Quantitative model of the stability-based apoptotic threshold lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [31, 34, 37, 42, 48, 55, 57]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 39, 41]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 23, 45]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [37]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [0, 32]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [41, 44]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 10, 21, 34, 49]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [25, 42, 58]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 20, 31, 45, 57]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [37, 55]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 19, 23, 52]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [25, 26, 27, 40]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TP53\", \"PML\", \"Daxx\", \"AXIN1\", \"SIAH1\", \"SIAH2\", \"MDM2\", \"PIN1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}